 JAFFER A AJANI
| Title | Professor |
|---|
| Institution | MD Anderson |
|---|
| Department | GI Medical Oncology |
|---|
| Address | 1400 Holcombe Blvd
Houston TX 77030-4008
|
|---|
| vCard | Download vCard |
|---|
|
|
|
 Additional Tools and Researcher Information Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
-
Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018 May 03; 9(1):1777. PMID: 29725014.
-
Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat Commun. 2017 10 19; 8(1):1050. PMID: 29051489.
-
Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, Cheong JH, Jeong W, Cho JY, Kim J, Chae J, Lee J, Kang WK, Kim S, Noh SH, Ajani JA, Lee JS. Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clin Cancer Res. 2017 Jul 26. PMID: 28747339.
-
Yi J, Lu L, Yanger K, Wang W, Sohn BH, Stanger BZ, Zhang M, Martin JF, Ajani JA, Chen J, Lee JS, Song S, Johnson RL. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ. Hepatology. 2016 Nov; 64(5):1757-1772. PMID: 27531557.
-
Lee KW, Lee SS, Hwang JE, Jang HJ, Lee HS, Oh SC, Lee SH, Sohn BH, Kim SB, Shim JJ, Jeong W, Cha M, Cheong JH, Cho JY, Lim JY, Park ES, Kim SC, Kang YK, Noh SH, Ajani JA, Lee JS. Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. Clin Cancer Res. 2016 Dec 15; 22(24):6228-6235. PMID: 27654712.
-
Sudo K, Wang X, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Rice DC, Lee JH, Weston B, Bhutani MS, Hiremath A, Charalampakis N, Komaki R, Blum MA, Swisher SG, Maru DM, Skinner HD, Garris JL, Rogers JE, Hofstetter WL, Ajani JA. A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. J Natl Compr Canc Netw. 2016 Feb; 14(2):173-9. PMID: 26850487.
-
Shiozaki H, Elimova E, Slack RS, Chen HC, Staerkel GA, Sneige N, Shimodaira Y, Sagebiel T, Lee JH, Bhutani MS, Das P, Mansfield PF, Estrella JS, Badgwell BD, Ajani JA. Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. J Surg Oncol. 2016 Jan; 113(1):29-35. PMID: 26603684.
-
Kneuertz PJ, Hofstetter WL, Chiang YJ, Das P, Blum M, Elimova E, Mansfield P, Ajani J, Badgwell B. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ? Ann Surg Oncol. 2016 Feb; 23(2):626-32. PMID: 26564243.
-
Pujara D, Mansfield P, Ajani J, Blum M, Elimova E, Chiang YJ, Das P, Badgwell B. Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. J Surg Oncol. 2015 Dec; 112(8):883-7. PMID: 26482869.
-
Charalampakis N, Xiao L, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Planjery V, Rogers JE, Matamoros A, Sagebiel T, Das P, Lee JH, Bhutani MS, Weston B, Estrella JS, Badgwell BD, Ajani JA. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology. 2015 Nov; 89(6):305-10. PMID: 26393501.
-
Chen Q, Song S, Wei S, Liu B, Honjo S, Scott A, Jin J, Ma L, Zhu H, Skinner HD, Johnson RL, Ajani JA. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. Oncotarget. 2015 Sep 22; 6(28):25883-96. PMID: 26317542.
-
Elimova E, Ajani JA. Surgical Resection First for Localized Gastric Adenocarcinoma: Are There Adjuvant Options? J Clin Oncol. 2015 Oct 1; 33(28):3085-91. PMID: 26324361.
-
Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer. 2015 Nov; 51(17):2545-52. PMID: 26321501.
-
Sharma P, Katzka DA, Gupta N, Ajani J, Buttar N, Chak A, Corley D, El-Serag H, Falk GW, Fitzgerald R, Goldblum J, Gress F, Ilson DH, Inadomi JM, Kuipers EJ, Lynch JP, McKeon F, Metz D, Pasricha PJ, Pech O, Peek R, Peters JH, Repici A, Seewald S, Shaheen NJ, Souza RF, Spechler SJ, Vennalaganti P, Wang K. Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology. 2015 Nov; 149(6):1599-606. PMID: 26296479.
-
Elimova E, Shiozaki H, Slack RS, Chen HC, Wadhwa R, Sudo K, Charalampakis N, Hiremath A, Estrella JS, Matamoros A, Sagebiel T, Das P, Rogers JE, Garris JL, Blum MA, Badgwell B, Ajani JA. Early versus Delayed Therapy of Advanced Gastric Cancer Patients--Does It Make a Difference? Oncology. 2015; 89(4):215-20. PMID: 26159599.
-
Elimova E, Ajani JA. Time-to-Treatment Failure As the Primary End Point of a First-Line Advanced Gastric Cancer Randomized Trial: How Confused Would You Want Us to Be? J Clin Oncol. 2015 Jul 20; 33(21):2410. PMID: 26077236.
-
Badgwell B, Ajani J, Blum M, Ho L, Fournier K, Chiang YJ, Matamoros A, Das P, Mansfield P. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Ann Surg Oncol. 2016 Jan; 23(1):156-62. PMID: 26059652.
-
Bodoky G, Scheulen ME, Rivera F, Jassem J, Carrato A, Moiseyenko V, Vynnychenko I, Prausová J, Van Laethem JL, Cascinu S, Ajani JA. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). J Gastrointest Cancer. 2015 Jun; 46(2):109-17. PMID: 25707610.
-
Sanchez-Espiridion B, Liang D, Ajani JA, Liang S, Ye Y, Hildebrandt MA, Gu J, Wu X. Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. Clin Gastroenterol Hepatol. 2015 Oct; 13(10):1730-1737.e9. PMID: 25998788.
-
Badgwell B, Blum M, Estrella J, Chiang YJ, Das P, Matamoros A, Fournier K, Mansfield P, Ajani J. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg. 2015 Jul; 221(1):83-90. PMID: 26002780.
-
Badgwell B, Roy-Chowdhuri S, Chiang YJ, Matamoros A, Blum M, Fournier K, Mansfield P, Ajani J. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol. 2015 Jun; 111(7):875-81. PMID: 25872485.
-
Charalampakis N, Elimova E, Shimodaira Y, Shiozaki H, Wadhwa R, Ajani JA. Biologics in combination with chemotherapy for gastric cancer: is this the answer? Expert Opin Pharmacother. 2015 May; 16(7):955-60. PMID: 25850442.
-
Elimova E, Wadhwa R, Shiozaki H, Sudo K, Estrella JS, Badgwell BD, Das P, Matamoros A, Song S, Ajani JA. Molecular biomarkers in gastric cancer. J Natl Compr Canc Netw. 2015 Apr; 13(4):e19-29. PMID: 26052595.
-
Neishaboori N, Wadhwa R, Nogueras-González GM, Elimova E, Shiozaki H, Sudo K, Charalampakis N, Hiremath A, Lee JH, Bhutani MS, Weston B, Blum MA, Rogers JE, Garris JL, Rice DC, Komaki R, Swisher SG, Skinner HD, Hofstetter WL, Ajani JA. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. Oncology. 2015; 89(2):65-9. PMID: 25765719.
-
Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, Wu TT, Johnson RL, Hung MC, Ajani JA. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res. 2015 Jun 1; 21(11):2580-90. PMID: 25739674.
-
Shiozaki H, Slack R, Sudo K, Elimova E, Wadhwa R, Chen HC, Skinner HD, Komaki R, Lee JH, Weston B, Bhutani MS, Blum MA, Rogers JE, Maru DM, Hofstetter WL, Ajani JA. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology. 2015; 88(6):332-6. PMID: 25765098.
-
Ajani JA, Song S, Hochster HS, Steinberg IB. Introduction. Semin Oncol. 2015 Apr; 42 Suppl 1:S1-2. PMID: 25839663.
-
Lin SH, Wang J, Allen PK, Correa AM, Maru DM, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol. 2015 Feb; 6(1):45-52. PMID: 25642337.
-
Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, Das P, Denlinger C, Fanta P, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Jasperson K, Keswani RN, Kleinberg LR, Korn WM, Leong S, Lockhart AC, Mulcahy MF, Orringer MB, Posey JA, Poultsides GA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Washington MK, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015 Feb; 13(2):194-227. PMID: 25691612.
-
Ajani JA, Song S, Hochster HS, Steinberg IB. Cancer stem cells: the promise and the potential. Semin Oncol. 2015 Apr; 42 Suppl 1:S3-17. PMID: 25839664.
-
Ajani JA. After local therapy for esophageal cancer, should we continue to survey patients and, if so, why and how? J Natl Compr Canc Netw. 2015 Jan; 13(1):2-3. PMID: 25583763.
-
Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Ylstra B, van Grieken N, Rha SY, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, Ajani JA, Boussioutas A, Yeoh KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, Zur Hausen A, Speed TP, Grabsch HI, Tan P. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut. 2015 Nov; 64(11):1721-31. PMID: 25385008.
-
Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: a 2014 update. World J Gastroenterol. 2014 Oct 14; 20(38):13637-47. PMID: 25320502.
-
Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct; 15(11):1224-35. PMID: 25240821.
-
Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, Blum MA, Lee JH, Bhutani MS, Weston B, Ross WA, Komaki R, Rice DC, Swisher SG, Hofstetter WL, Maru DM, Skinner HD, Ajani JA. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014 Oct 20; 32(30):3400-5. PMID: 25225435.
-
Skinner HD, Lee JH, Bhutani MS, Weston B, Hofstetter W, Komaki R, Shiozaki H, Wadhwa R, Sudo K, Elimova E, Song S, Ye Y, Huang M, Ajani J, Wu X. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer. 2014 Dec 1; 120(23):3635-41. PMID: 25091571.
-
Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol. 2014 Aug; 9(8):1202-6. PMID: 25157774.
-
Taketa T, Sudo K, Correa AM, Wadhwa R, Shiozaki H, Elimova E, Campagna MC, Blum MA, Skinner HD, Komaki RU, Lee JH, Bhutani MS, Weston BR, Rice DC, Swisher SG, Maru DM, Hofstetter WL, Ajani JA. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014 Aug; 12(8):1139-44. PMID: 25099446.
-
Siegel EM, Eschrich S, Winter K, Riggs B, Berglund A, Ajidahun A, Simko J, Moughan J, Ajani J, Magliocco A, Elahi A, Hoffe S, Shibata D. Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study. Dis Colon Rectum. 2014 Aug; 57(8):941-57. PMID: 25003289; PMCID: PMC4100249.
-
Patel VR, Hofstetter WL, Correa AM, Agarwal A, Rashid A, Bhutani MS, Lin SH, Ajani JA, Swisher SG, Maru DM. Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. Ann Thorac Surg. 2014 Sep; 98(3):1064-71. PMID: 25038008.
-
Li Y, Liu Z, Liu H, Wang LE, Onodera H, Suzuki A, Suzuki K, Wadhwa R, Elimova E, Sudo K, Shiozaki H, Estrella J, Lee JS, Song S, Tan D, Ajani JA, Wei Q. Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients. Carcinogenesis. 2014 Sep; 35(9):2031-8. PMID: 24990617.
-
Sun Y, Gu J, Ajani JA, Chang DW, Wu X, Stroehlein JR. Genetic and intermediate phenotypic susceptibility markers of gastric cancer in Hispanic Americans: a case-control study. Cancer. 2014 Oct 1; 120(19):3040-8. PMID: 24962126.
-
Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, Skinner HD, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, Ajani JA. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014; 86(5-6):336-9. PMID: 24925190; PMCID: PMC4105702.
-
Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B, Lee JH, Wadhwa R, Sudo K, Stroehlein JR, Martin JF, Hung MC, Johnson RL. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res. 2014 Aug 1; 74(15):4170-82. PMID: 24906622; PMCID: PMC4136429.
-
Sudo K, Elimova E, Skinner HD, Hofstetter WL, Ajani JA. Critical appraisal of locoregional failure and systemic disease progression after preoperative chemoradiation of esophageal adenocarcinoma. Reply to R. Gertler et al. J Clin Oncol. 2014 Jul 1; 32(19):2112-3. PMID: 24868018.
-
Honjo S, Ajani JA, Scott AW, Chen Q, Skinner HD, Stroehlein J, Johnson RL, Song S. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol. 2014 Aug; 45(2):567-74. PMID: 24859412.
-
Ajani JA, Swisher SG. Three angels are dancing on the head of the esophageal cancer pin, but shouldn't we not topple one or two? Ann Surg Oncol. 2014 Sep; 21(9):2815-6. PMID: 24756809.
-
Shen R, Liu H, Wen J, Liu Z, Wang LE, Wang Q, Tan D, Ajani JA, Wei Q. Genetic polymorphisms in the microRNA binding-sites of the thymidylate synthase gene predict risk and survival in gastric cancer. Mol Carcinog. 2015 Sep; 54(9):880-8. PMID: 24756984.
-
Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014 Apr 15; 5(7):1837-45. PMID: 24742823.
-
Wadhwa R, Elimova E, Shiozaki H, Sudo K, Blum MA, Estrella JS, Chen Q, Song S, Ajani JA. Anti-angiogenic agent ramucirumab: meaningful or marginal? Expert Rev Anticancer Ther. 2014 Apr; 14(4):367-79. PMID: 24605771.
-
Wang Q, Liu H, Xiong H, Liu Z, Wang LE, Qian J, Muddasani R, Lu V, Tan D, Ajani JA, Wei Q. Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer. Mol Carcinog. 2015 Jun; 54(6):449-58. PMID: 24302553.
-
Amini A, Ajani J, Komaki R, Allen PK, Minsky BD, Blum M, Xiao L, Suzuki A, Hofstetter W, Swisher S, Gomez D, Liao Z, Lee JH, Bhutani MS, Welsh JW. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14. PMID: 24197760.
-
Blum MA, Taketa T, Sudo K, Wadhwa R, Skinner HD, Ajani JA. Chemoradiation for esophageal cancer. Thorac Surg Clin. 2013 Nov; 23(4):551-8. PMID: 24199704.
-
Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM, Lee JH, Bhutani MS, Weston B, Baladandayuthapani V, Yao Y, Honjo S, Scott AW, Skinner HD, Johnson RL, Berry D. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2014 Feb; 8(1):142-9. PMID: 24210755; PMCID: PMC3946849.
-
Dhupar R, Correa AM, Ajani J, Betancourt S, Mehran RJ, Swisher SG, Hofstetter WL. Concordance of studies for nodal staging is prognostic for worse survival in esophageal cancer. Dis Esophagus. 2014 Nov-Dec; 27(8):770-6. PMID: 24152134.
-
Sudo K, Taketa T, Correa AM, Campagna MC, Wadhwa R, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, Skinner HD, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol. 2013 Dec 1; 31(34):4306-10. PMID: 24145339.
-
Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013 Nov; 10(11):643-55. PMID: 24061039; PMCID: PMC3927982.
-
Wadhwa R, Taketa T, Correa AM, Sudo K, Campagna MC, Blum MA, Komaki R, Skinner H, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher S, Hofstetter WL, Ajani JA. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013; 85(4):204-7. PMID: 24051869.
-
Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013 Nov 1; 31(31):3935-43. PMID: 24043745.
-
Gunderson LL, Moughan J, Ajani JA, Pedersen JE, Winter KA, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013 Nov 15; 87(4):638-45. PMID: 24035327.
-
Li Y, Liu Z, Liu H, Wang LE, Tan D, Ajani JA, Wei QY. ERCC1 and ERCC2 variants predict survival in gastric cancer patients. PLoS One. 2013; 8(9):e71994. PMID: 24023723.
-
Suzuki A, Xiao L, Taketa T, Sudo K, Wadhwa R, Blum MA, Skinner H, Komaki R, Weston B, Lee JH, Bhutani MS, Rice DC, Maru DM, Erasmus J, Swisher SG, Hofstetter WL, Ajani JA. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol. 2013 Nov; 24(11):2854-9. PMID: 23994746.
-
Xu E, Gu J, Hawk ET, Wang KK, Lai M, Huang M, Ajani J, Wu X. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis. 2013 Dec; 34(12):2750-6. PMID: 23996928; PMCID: PMC3845893.
-
Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov; 24(11):2844-9. PMID: 23975663; PMCID: PMC3937600.
-
Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z, Lin SH. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013 Aug 1; 86(5):885-91. PMID: 23845841.
-
Xu E, Gong Y, Gu J, Jie L, Ajani JA, Wu X. Risk assessment of esophageal adenocarcinoma using ?-H2AX assay. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1797-804. PMID: 23904462.
-
Ajani JA, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha R, Carrato A, Ferry D, Moiseyenko V. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer. 2013 Nov; 49(17):3616-24. PMID: 23899532.
-
Taketa T, Xiao L, Sudo K, Suzuki A, Wadhwa R, Blum MA, Lee JH, Weston B, Bhutani MS, Skinner H, Komaki R, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology. 2013; 85(2):95-9. PMID: 23860252.
-
Ajani JA. Challenges imposed by the complexity of cancer genome. Lancet Oncol. 2013 Jul; 14(8):e291-2. PMID: 23816294.
-
Xu E, Sun W, Gu J, Chow WH, Ajani JA, Wu X. Association of mitochondrial DNA copy number in peripheral blood leukocytes with risk of esophageal adenocarcinoma. Carcinogenesis. 2013 Nov; 34(11):2521-4. PMID: 23803692.
-
Wadhwa R, Taketa T, Sudo K, Blum-Murphy M, Ajani JA. Ramucirumab: a novel antiangiogenic agent. Future Oncol. 2013 Jun; 9(6):789-95. PMID: 23718298.
-
Murphy CC, Correa AM, Ajani JA, Komaki RU, Welsh JW, Swisher SG, Hofstetter WL. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg. 2013 Aug; 17(8):1359-69. PMID: 23715646.
-
Xu Y, Ma H, Yu H, Liu Z, Wang LE, Tan D, Muddasani R, Lu V, Ajani JA, Wang Y, Wei Q. The miR-184 binding-site rs8126 T>C polymorphism in TNFAIP2 is associated with risk of gastric cancer. PLoS One. 2013; 8(5):e64973. PMID: 23724109; PMCID: PMC3665554.
-
Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, McMillian NR, Sundar H. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 May 1; 11(5):531-46. PMID: 23667204.
-
Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus. 2014 Feb-Mar; 27(2):168-75. PMID: 23621168.
-
Taketa T, Sudo K, Wadhawa R, Blum MM, Ajani JA. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013 Apr; 15(2):146-51. PMID: 23355076.
-
Song S, Maru DM, Ajani JA, Chan CH, Honjo S, Lin HK, Correa A, Hofstetter WL, Davila M, Stroehlein J, Mishra L. Loss of TGF-? adaptor ?2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. Cancer Res. 2013 Apr 1; 73(7):2159-69. PMID: 23536563; PMCID: PMC3745222.
-
Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2013 Mar; 6(3):196-205. PMID: 23466817; PMCID: PMC3608471.
-
Wadhwa R, Taketa T, Sudo K, Blum MA, Ajani JA. Modern oncological approaches to gastric adenocarcinoma. Gastroenterol Clin North Am. 2013 Jun; 42(2):359-69. PMID: 23639645.
-
Murphy CC, Hofstetter WL, Correa AM, Ajani JA, Komaki RU, Swisher SG. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting. Dis Esophagus. 2013 Sep-Oct; 26(7):708-15. PMID: 23350713.
-
Blum MA, Takashi T, Suzuki A, Ajani JA. Management of localized gastric cancer. J Surg Oncol. 2013 Mar; 107(3):265-70. PMID: 23303654.
-
Strong VE, D'Amico TA, Kleinberg L, Ajani J. Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw. 2013 Jan 1; 11(1):60-6. PMID: 23307982.
-
Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. 2013 May; 24(5):1262-6. PMID: 23247658.
-
Murphy MA, Taketa T, Sudo K, Lee JH, Ajani JA. Surveillance for esophageal cancer: does it make sense? J Natl Compr Canc Netw. 2012 Dec 1; 10(12):1590-2. PMID: 23221793.
-
Song S, Ajani JA. The role of microRNAs in cancers of the upper gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2013 Feb; 10(2):109-18. PMID: 23165235; PMCID: PMC3855852.
-
Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012 Dec 10; 30(35):4344-51. PMID: 23150707; PMCID: PMC3515768.
-
Das P, Strong VE, Ajani JA. Adjuvant and neoadjuvant therapy for gastric cancer: taking stock of the options. Gastrointest Cancer Res. 2012 Nov; 5(6):203-4. PMID: 23293702.
-
Swisher S, Ajani J, Correa A, Komaki R, Hofstetter W. Minimally invasive versus open oesophagectomy for oesophageal cancer. Lancet. 2012 Sep 8; 380(9845):883; author reply 885-6. PMID: 22959377.
-
Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2013 Jun; 52(5):1002-9. PMID: 22950385.
-
Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4. PMID: 22964903; PMCID: PMC3832345.
-
Taketa T, Ohigashi S, Suzuki K, Sudo K, Shiozaki H, Suzuki A, Blum MA, Ajani JA, Onodera H. Paraneoplastic neurological syndromes associated with gastric cancer: a case report and review of the literature. Clin J Gastroenterol. 2012 Oct; 5(5):355-60. PMID: 26181075.
-
Marks JL, Hofstetter W, Correa AM, Mehran RJ, Rice D, Roth J, Walsh G, Vaporciyan A, Erasmus J, Chang J, Maru D, Lee JH, Lee J, Ajani JA, Swisher SG. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg. 2012 Oct; 94(4):1126-32; discussion 1132-3. PMID: 22921233.
-
Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Hölscher A, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A, van Lanschot J, Ychou M, Otto F. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 2012 Nov; 48(16):2941-53. PMID: 22921186.
-
Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 1; 84(5):1078-85. PMID: 22867894; PMCID: PMC3923623.
-
Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404. PMID: 22853875; PMCID: PMC3869451.
-
Blum MA, Ajani JA. Chemoradiation: Gastro-oesophageal cancer--is CROSSing over so hard to do? Nat Rev Clin Oncol. 2012 Sep; 9(9):493-4. PMID: 22825372.
-
Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012 Oct; 23(10):2638-42. PMID: 22831985; PMCID: PMC3457750.
-
Jiang Y, Ajani JA. Anal margin cancer: current situation and ongoing trials. Curr Opin Oncol. 2012 Jul; 24(4):448-53. PMID: 22581355.
-
Wu Y, Grabsch H, Ivanova T, Tan IB, Murray J, Ooi CH, Wright AI, West NP, Hutchins GG, Wu J, Lee M, Lee J, Koo JH, Yeoh KG, van Grieken N, Ylstra B, Rha SY, Ajani JA, Cheong JH, Noh SH, Lim KH, Boussioutas A, Lee JS, Tan P. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut. 2013 Aug; 62(8):1100-11. PMID: 22735568.
-
Suzuki A, Xiao L, Taketa T, Blum MA, Matamoros A, Chien PL, Mansfield PF, Fournier KF, Weston B, Lee JH, Bhutani MS, Estrella JS, Delclos ME, Krishnan S, Das P, Ajani JA. Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. Oncology. 2012; 82(6):347-51. PMID: 22677933.
-
Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012 Jul 1; 30(19):2327-33. PMID: 22585691; PMCID: PMC4517071.
-
Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo L, Labaff AM, Liu D, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar NS, Wang KK, Wu Y, Wang H, Ajani J, Hung MC. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 2012 Mar 20; 21(3):374-87. PMID: 22439934.
-
Amini A, Xiao L, Allen PK, Suzuki A, Hayashi Y, Liao Z, Hofstetter W, Crane C, Komaki R, Bhutani MS, Lee JH, Ajani JA, Welsh J. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys. 2012 Jun 1; 83(2):e231-9. PMID: 22436793; PMCID: PMC3795392.
-
Hayashi Y, Blum MA, Ajani JA. Advanced gastroesophageal carcinoma: an update on the current therapeutic landscape. Onkologie. 2012; 35(4):204-9. PMID: 22488092.
-
Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, Palmer M, Mohan R, Swisher SG, Hofstetter WL, Ajani JA, Cox JD. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 1; 83(3):e345-51. PMID: 22417808; PMCID: PMC3923631.
-
Blum MA, Ajani JA. Therapy: localized gastric cancer--a CLASSIC shift in the paradigm? Nat Rev Gastroenterol Hepatol. 2012 Apr; 9(4):194-5. PMID: 22392288.
-
Kountourakis P, Ajani JA, Davila M, Lee JH, Bhutani MS, Izzo JG. Barrett's Esophagus: A Review of Biology and Therapeutic Approaches. Gastrointest Cancer Res. 2012 Mar; 5(2):49-57. PMID: 22690258.
-
Ajani JA, Blum MA, Estrella JS, Das P, Fournier KF. Gastric cancer: apples will always be apples. J Clin Oncol. 2012 Mar 20; 30(9):1017-8; author reply 1019-20. PMID: 22331947.
-
Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012; 82(2):108-13. PMID: 22328056.
-
Ajani JA, Swisher SG. Preoperative chemotherapy for localized squamous cell carcinoma of the esophagus? We should go back to the drawing board! Ann Surg Oncol. 2012 Jan; 19(1):3-4. PMID: 21989665.
-
Pan JY, Ajani JA, Gu J, Gong Y, Qin A, Quin A, Hung M, Wu X, Izzo JG. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer. 2012 Sep 1; 118(17):4346-53. PMID: 22213102; PMCID: PMC3831524.
-
Harvin JA, Lahat G, Correa AM, Lee J, Maru D, Ajani J, Marom EM, Welsh J, Bhutani MS, Walsh G, Roth J, Mehran R, Vaporciyan A, Rice D, Swisher S, Hofstetter W. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins. J Thorac Cardiovasc Surg. 2012 Feb; 143(2):412-20. PMID: 22172216.
-
Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Mehran RJ, Rice DC, Suzuki A, Lee JH, Bhutani MS, Welsh J, Lin SH, Maru DM, Swisher SG, Ajani JA. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus. 2012 Sep-Oct; 25(7):614-22. PMID: 22150920.
-
Chakravarty T, Crane CH, Ajani JA, Mansfield PF, Briere TM, Beddar AS, Mok H, Reed VK, Krishnan S, Delclos ME, Das P. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012 Jun 1; 83(2):581-6. PMID: 22137021.
-
Thosani N, Singh H, Kapadia A, Ochi N, Lee JH, Ajani J, Swisher SG, Hofstetter WL, Guha S, Bhutani MS. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc. 2012 Feb; 75(2):242-53. PMID: 22115605.
-
Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Wa Cheng K, Hall H, Zhang D, Lu Y, Ravoori M, Kundra V, Ajani J, Lee JS, Ki Hong W, Mills GB. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther. 2011 Dec; 10(12):2350-62. PMID: 21992792; PMCID: PMC3237863.
-
Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012 May 15; 118(10):2632-40. PMID: 22565611; PMCID: PMC3747650.
-
Kim JY, Correa AM, Vaporciyan AA, Roth JA, Mehran RJ, Walsh GL, Rice DC, Ajani JA, Maru DM, Bhutani MS, Welsh J, Marom EM, Swisher SG, Hofstetter WL. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg. 2012 Jan; 93(1):207-12; discussion 212-3. PMID: 21962263; PMCID: PMC4041623.
-
Blum MA, Ajani JA. Many a mickle makes a muckle. Translating a gastric cancer phenotype into a bigger thing. Onkologie. 2011; 34(10):499-500. PMID: 21985847.
-
Ajani JA, Mangu PB, Burstein HJ. Peek before you treat? Is it a fantasy or reality? J Oncol Pract. 2011 Sep; 7(5):338-9. PMID: 22211134.
-
Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 2011 Aug 1; 9(8):830-87. PMID: 21900218.
-
Ajani JA. Crescendos and decrescendos: gastric and esophageal cancers. J Natl Compr Canc Netw. 2011 Aug 1; 9(8):811-3. PMID: 21900215.
-
Glasgow RE, Ilson DH, Hayman JA, Gerdes H, Mulcahy MF, Ajani JA. Modern approaches to localized cancer of the esophagus. J Natl Compr Canc Netw. 2011 Aug 1; 9(8):902-11. PMID: 21900220.
-
Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, Zelman D, Ajani JA. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol. 2011 Aug 20; 29(24):3328-30. PMID: 21788567.
-
Estrella JS, Hofstetter WL, Correa AM, Swisher SG, Ajani JA, Lee JH, Bhutani MS, Abraham SC, Rashid A, Maru DM. Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma. Am J Surg Pathol. 2011 Jul; 35(7):1045-53. PMID: 21602659.
-
Welsh J, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep. 2011 Jun; 13(3):157-67. PMID: 21365188; PMCID: PMC4086148.
-
Blum M, Suzuki A, Ajani JA. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol. 2011 Jun; 7(6):715-26. PMID: 21675835.
-
Ajani JA, Blum MA, Welsh J, Hofstetter WL, Swisher SG. Celebrate or calibrate? We say calibrate. J Clin Oncol. 2011 Jul 1; 29(19):2732; author reply 2732-3. PMID: 21606421.
-
Khokhar NZ, Jiang Y, Benson AB, Ajani JA, Mulcahy MF. Refining docetaxel-containing therapy for gastric cancer. Gastrointest Cancer Res. 2011 May; 4(3):96-105. PMID: 22043325; PMCID: PMC3201643.
-
Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee JS, Tellez MS, Tan P. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011 Aug; 141(2):476-85, 485.e1-11. PMID: 21684283; PMCID: PMC3152688.
-
Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys. 2012 Apr 1; 82(5):1967-72. PMID: 21507583; PMCID: PMC3796353.
-
Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, Dong L, Zhu XR, Likhacheva A, Liao Z, Hofstetter WL, Ajani JA, Cox JD. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys. 2011 Dec 1; 81(5):1336-42. PMID: 21470796; PMCID: PMC4086056.
-
Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011 Nov 1; 117(21):4823-33. PMID: 21456015; PMCID: PMC3144261.
-
Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, Kim SM, Kim SB, Kim H, Hong SW, Park YN, Noh SH, Park ES, Chu IS, Hong WK, Ajani JA, Lee JS. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res. 2011 Apr 1; 17(7):1850-7. PMID: 21447720; PMCID: PMC3078023.
-
Ajani JA. GCR Graduates From Nursery School on a Fast Track to Editorial Excellence. Gastrointest Cancer Res. 2011 Mar; 4(2):39. PMID: 21673873.
-
Cohen DJ, Ajani J. An expert opinion on esophageal cancer therapy. Expert Opin Pharmacother. 2011 Feb; 12(2):225-39. PMID: 21226634.
-
Hu Y, Correa AM, Hoque A, Guan B, Ye F, Huang J, Swisher SG, Wu TT, Ajani JA, Xu XC. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer. 2011 Jan 1; 128(1):132-43. PMID: 20309880; PMCID: PMC2937084.
-
Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82(1):468-74. PMID: 21123005.
-
Kim SM, Park YY, Park ES, Cho JY, Izzo JG, Zhang D, Kim SB, Lee JH, Bhutani MS, Swisher SG, Wu X, Coombes KR, Maru D, Wang KK, Buttar NS, Ajani JA, Lee JS. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One. 2010; 5(11):e15074. PMID: 21152079.
-
Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, Walsh GL, Mehran RJ, Lee JH, Bhutani MS, Dekovich A, Swisher SG, Ajani JA. The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy. Cancer. 2010 Dec 15; 116(24):5619-27. PMID: 21136578.
-
Jiang Y, Ajani JA. Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol. 2010 Nov; 26(6):640-6. PMID: 20827183.
-
Correa MC, Deus HF, Vasconcelos AT, Hayashi Y, Ajani JA, Patnana SV, Almeida JS. AGUIA: autonomous graphical user interface assembly for clinical trials semantic data services. BMC Med Inform Decis Mak. 2010; 10:65. PMID: 20977768; PMCID: PMC2987967.
-
Kountourakis P, Correa AM, Hofstetter WL, Lee JH, Bhutani MS, Rice DC, Komaki R, Maru DM, Ross WA, Vaporciyan A, Swisher SG, Ajani JA. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer. 2011 Mar 1; 117(5):925-30. PMID: 20960497; PMCID: PMC3080168.
-
Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol. 2010 Dec 1; 28(34):5061-6. PMID: 20956625.
-
Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer. 2010 Oct 1; 116(19):4487-94. PMID: 20629031.
-
Swisher SG, Hofstetter W, Komaki R, Correa AM, Erasmus J, Lee JH, Liao Z, Maru D, Mehran R, Patel S, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Ajani JA. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg. 2010 Sep; 90(3):892-8; discussion 898-9. PMID: 20732514.
-
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010 Sep 1; 116(17):4007-13. PMID: 20564111; PMCID: PMC3831519.
-
Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010 Sep; 90(3):884-90; discussion 890-1. PMID: 20732513.
-
Gaur P, Sepesi B, Hofstetter WL, Correa AM, Bhutani MS, Watson TJ, Swisher SG. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer. 2011 Jan 1; 117(1):63-9. PMID: 20803613.
-
Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010; 78(5-6):316-22. PMID: 20699623.
-
Jiang Y, Mackley H, Cheng H, Ajani JA. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. Biomark Med. 2010 Aug; 4(4):535-41. PMID: 20701442.
-
Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Wang KK, Wu X. Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila). 2010 Sep; 3(9):1176-86. PMID: 20651033.
-
Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer. 2010 Jun 1; 116(11):2511-8. PMID: 20301114.
-
Shah MA, Ajani JA. Gastric cancer--an enigmatic and heterogeneous disease. JAMA. 2010 May 5; 303(17):1753-4. PMID: 20442394.
-
Ajani JA. In the ring with a raging bull: unresectable localized esophageal carcinoma. Onkologie. 2010; 33(5):220-1. PMID: 20502055.
-
Ajani JA. Resectable esophageal cancer: surgery as primary therapy is not the answer, but then, what is and why? J Clin Oncol. 2010 May 20; 28(15):e243-4; author reply e245. PMID: 20368554.
-
Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, Rice DC, Yao JC, Maru DM, Hofstetter WL, Phan AT, Swisher SG. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 1; 116(7):1656-63. PMID: 20143431.
-
Das P, Jiang Y, Lee JH, Bhutani MS, Ross WA, Mansfield PF, Ajani JA. Multimodality approaches to localized gastric cancer. J Natl Compr Canc Netw. 2010 Apr; 8(4):417-25. PMID: 20410334.
-
Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G. Gastric cancer. J Natl Compr Canc Netw. 2010 Apr; 8(4):378-409. PMID: 20410333.
-
Zachariah B, Gwede CK, James J, Ajani J, Chin LJ, Donath D, Rosenthal SA, Kane BL, Rotman M, Berk L, Kachnic LA. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. J Natl Cancer Inst. 2010 Apr 21; 102(8):547-56. PMID: 20339140.
-
Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010 Mar 15; 116(6):1446-53. PMID: 20108336.
-
Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010 Mar 20; 28(9):1547-53. PMID: 20159816.
-
Jiang Y, Mackley H, Cheng H, Ajani JA. Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy? J Natl Compr Canc Netw. 2010 Jan; 8(1):135-44. PMID: 20064295.
-
Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H, Wang X, Ajani JA. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009 Nov 15; 115(22):5184-92. PMID: 19685531.
-
Guan X, Zhao H, Niu J, Tang D, Ajani JA, Wei Q. The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol. 2009; 9:77. PMID: 19835575; PMCID: PMC2771032.
-
Braiteh F, Correa AM, Hofstetter WL, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Mehran RJ, Swisher SG, Ajani JA. Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapy. Cancer. 2009 Oct 1; 115(19):4450-8. PMID: 19562780.
-
Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, Ajani JA, Wu X. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009 Sep 15; 15(18):5744-52. PMID: 19737949; PMCID: PMC2745487.
-
Goodarzi M, Correa AM, Ajani JA, Swisher SG, Hofstetter WL, Guha S, Deavers MT, Rashid A, Maru DM. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. Mod Pathol. 2009 Dec; 22(12):1612-21. PMID: 19734842.
-
Al-Batran SE, Ajani JA. Accomplishments in 2008 in the management of advanced gastroesophageal cancer. Gastrointest Cancer Res. 2009 Sep; 3(5 Supplement 2):S58-61. PMID: 20011567.
-
Ajani JA. Accomplishments in gastrointestinal oncology in 2008: conclusion. Gastrointest Cancer Res. 2009 Sep; 3(5 Supplement 2):S79. PMID: 20011571.
-
Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer. 2009 Aug 15; 115(16):3609-17. PMID: 19526592.
-
Zhang Z, Chen Y, Chen Y, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Allen PK, Cox JD, Komaki R, Liao ZX. Outcomes with esophageal cancer radiation therapy. J Thorac Oncol. 2009 Jul; 4(7):880-8. PMID: 19458557.
-
Clark OH, Benson AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A, Kulke MH, Kvols L, Salem R, Saltz L, Shah MH, Shibata S, Strosberg JR, Yao JC. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009 Jul; 7(7):712-47. PMID: 19635226.
-
Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M. Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience. Oncology. 2009; 77(2):75-81. PMID: 19571599; PMCID: PMC2790774.
-
Guan X, Zhao H, Niu J, Tan D, Ajani JA, Wei Q. Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer. J Exp Clin Cancer Res. 2009; 28:94. PMID: 19566948.
-
McCurdy M, McAleer MF, Wei W, Ezhil M, Johnson V, Khan M, Baker J, Luo D, Ajani J, Guerrero T. Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 1; 76(3):816-23. PMID: 19525073; PMCID: PMC3696888.
-
Chen G, Izzo J, Demizu Y, Wang F, Guha S, Wu X, Hung MC, Ajani JA, Huang P. Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol. Antioxid Redox Signal. 2009 May; 11(5):1083-95. PMID: 19187006; PMCID: PMC2842128.
-
Lagaly R, Horak A, Lee JH, Mansfield PF, Ajani JA. Patient with advanced gastric cancer responds twice to the same systemic therapy. Gastrointest Cancer Res. 2009 May; 3(3):115-7. PMID: 19626154.
-
Xing J, Ajani JA, Chen M, Izzo J, Lin J, Chen Z, Gu J, Wu X. Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. Cancer Prev Res (Phila). 2009 May; 2(5):459-65. PMID: 19401529.
-
Ajani JA, Wang X, Izzo JG, Crane CH, Eng C, Skibber JM, Das P, Rashid A. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci. 2010 Apr; 55(4):1098-105. PMID: 19399614.
-
Ajani JA. Chemotherapy and radiation resistance: version 2.0. J Clin Oncol. 2009 Jun 1; 27(16):2735-6; author reply 2737-8. PMID: 19398570.
-
Bolton WD, Hofstetter WL, Francis AM, Correa AM, Ajani JA, Bhutani MS, Erasmus J, Komaki R, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Swisher SG. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009 Oct; 138(4):831-6. PMID: 19660349.
-
Maru DM, Luthra R, Correa AM, White-Cross J, Anandasabapathy S, Krishnan S, Guha S, Komaki R, Swisher SG, Ajani JA, Hofstetter WL, Rashid A. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer. 2009 Apr 1; 115(7):1576-85. PMID: 19156915.
-
Smith GL, Smith BD, Buchholz TA, Liao Z, Jeter M, Swisher SG, Hofstetter WL, Ajani JA, McAleer MF, Komaki R, Cox JD. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys. 2009 Jun 1; 74(2):482-9. PMID: 19289262.
-
Pan J, Lin J, Izzo JG, Liu Y, Xing J, Huang M, Ajani JA, Wu X. Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. Carcinogenesis. 2009 May; 30(5):785-92. PMID: 19270000.
-
Ajani JA. Future developments in esophageal cancer research. Gastroenterol Clin North Am. 2009 Mar; 38(1):183-8, x. PMID: 19327575.
-
Jiang Y, Kimchi E, Ajani JA. Localized squamous cell carcinoma of the esophagus: bimodality or trimodality approach? Future Oncol. 2009 Mar; 5(2):157-61. PMID: 19284374.
-
Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2009 Feb; 13(1):49-59. PMID: 19201649.
-
Brücher BL, Swisher SG, Königsrainer A, Zieker D, Hartmann J, Stein H, Kitagawa Y, Law S, Ajani JA. Response to preoperative therapy in upper gastrointestinal cancers. Ann Surg Oncol. 2009 Apr; 16(4):878-86. PMID: 19194759.
-
Javeri H, Xiao L, Rohren E, Komaki R, Hofstetter W, Lee JH, Maru D, Bhutani MS, Swisher SG, Wang X, Ajani JA. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer. 2009 Feb 1; 115(3):624-30. PMID: 19130466.
-
Yendamuri S, Swisher SG, Correa AM, Hofstetter W, Ajani JA, Francis A, Maru D, Mehran RJ, Rice DC, Roth JA, Walsh GL, Vaporciyan AA. Esophageal tumor length is independently associated with long-term survival. Cancer. 2009 Feb 1; 115(3):508-16. PMID: 19117343.
-
Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 2009 Feb 20; 27(6):857-71. PMID: 19164214.
-
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009 Mar 1; 27(7):1116-21. PMID: 19139424; PMCID: PMC2667813.
-
Ajani JA. Preoperative therapy for potentially resectable localized gastric cancer. Gastrointest Cancer Res. 2009 Jan; 3(1):36-7. PMID: 19343137; PMCID: PMC2661124.
-
Yin M, Hu Z, Tan D, Ajani JA, Wei Q. Molecular epidemiology of genetic susceptibility to gastric cancer: focus on single nucleotide polymorphisms in gastric carcinogenesis. Am J Transl Res. 2009; 1(1):44-54. PMID: 19966937.
-
Gusani NJ, Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. New pharmacological developments in the treatment of hepatocellular cancer. Drugs. 2009; 69(18):2533-40. PMID: 19943706.
-
Ajani JA, Izzo JG, Lee JS. Chemotherapy and radiotherapy resistance: complexity, reality, and promise. J Clin Oncol. 2009 Jan 1; 27(1):162-3; author reply 163. PMID: 19047300.
-
Cen P, Correa AM, Lee JH, Le JH, Maru D, Anandasabapathy S, Liao Z, Hofstetter WL, Swisher SG, Komaki R, Ross WA, Vaporciyan A, Ajani JA. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Dis Esophagus. 2009; 22(1):32-41. PMID: 19021684.
-
Izzo JG, Wu X, Wu TT, Huang P, Lee JS, Liao Z, Lee JH, Bhutani MS, Hofstetter W, Maru D, Hung MC, Ajani JA. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus. 2009; 22(2):127-32. PMID: 19021681.
-
Tetzlaff ED, Cheng JD, Ajani JA. Thromboembolism in gastrointestinal cancers. Gastrointest Cancer Res. 2008 Nov; 2(6):267-72. PMID: 19259275.
-
Ye Y, Wang KK, Gu J, Yang H, Lin J, Ajani JA, Wu X. Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila). 2008 Nov; 1(6):460-9. PMID: 19138993; PMCID: PMC2768267.
-
Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer. 2008 Oct 15; 113(8):2038-45. PMID: 18759326.
-
Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Ilson DH, Kleinberg LR, McAleer MF, Meropol NJ, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Swisher SG, Washington MK, Willett C, Wood DE, Wright CD, Yang G. Esophageal cancer. J Natl Compr Canc Netw. 2008 Oct; 6(9):818-49. PMID: 18926093.
-
Tetzlaff ED, Cheng JD, Ajani JA. Review of docetaxel in the treatment of gastric cancer. Ther Clin Risk Manag. 2008 Oct; 4(5):999-1007. PMID: 19209281; PMCID: PMC2621422.
-
Ajani JA. Gastroesophageal cancers: progress and problems. J Natl Compr Canc Netw. 2008 Oct; 6(9):813-4. PMID: 18998257.
-
Javeri H, Arora R, Correa AM, Hofstetter WL, Lee JH, Liao Z, McAleer MF, Maru D, Bhutani MS, Swisher SG, Izzo JG, Ajani JA. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer. 2008 Sep 15; 113(6):1302-8. PMID: 18623381.
-
Ajani JA. Molecular determinants of prognosis in oesophageal cancer patients treated with chemoradiation. Br J Cancer. 2008 Oct 7; 99(7):1195; author reply 1196. PMID: 18766183; PMCID: PMC2567093.
-
Maru DM, Khurana H, Rashid A, Correa AM, Anandasabapathy S, Krishnan S, Komaki R, Ajani JA, Swisher SG, Hofstetter WL. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008 Sep; 32(9):1404-11. PMID: 18670347.
-
Ajani JA. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer. 2008 Sep 1; 113(5):945-55. PMID: 18623382.
-
Ajani JA. Is the addition of cisplatin to S-1 better than S-1 alone for patients with advanced gastroesophageal cancer? Nat Clin Pract Oncol. 2008 Sep; 5(9):508-9. PMID: 18628737.
-
Ajani JA, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, Bradley J, Fromm M, Hornback D, Willett CG. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008 Oct 1; 26(28):4551-6. PMID: 18574157; PMCID: PMC2653130.
-
Ajani J. Therapy of localized esophageal cancer: it is time to reengineer our investigative strategies. Onkologie. 2008 Jul; 31(7):360-1. PMID: 18596381.
-
Ajani JA. Are capecitabine and oxaliplatin as effective as fluorouracil and cisplatin for gastroesophageal cancer? Nat Clin Pract Gastroenterol Hepatol. 2008 Aug; 5(8):414-5. PMID: 18560397.
-
Jiang Y, Kimchi ET, Montero AJ, Staveley-O'Carroll KF, Ajani JA. Upper gastrointestinal tumors: current status and future perspectives. Expert Rev Anticancer Ther. 2008 Jun; 8(6):975-91. PMID: 18533807.
-
Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2008 Jul; 12(3):253-68. PMID: 18501674.
-
Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, Ajani JA. Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus. 2008; 21(7):575-81. PMID: 18459989.
-
Ajani JA, Schmoll HJ. Accomplishments in 2007 in the management of advanced gastroesophageal cancer. Gastrointest Cancer Res. 2008 May; 2(3 Suppl):S47-50. PMID: 19352469.
-
Kim MM, Mansfield PF, Das P, Janjan NA, Badgwell BD, Phan AT, Delclos ME, Maru D, Ajani JA, Crane CH, Krishnan S. Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. Int J Radiat Oncol Biol Phys. 2008 May 1; 71(1):167-72. PMID: 18406886.
-
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008 Apr 23; 299(16):1914-21. PMID: 18430910.
-
Yen CJ, Izzo JG, Lee DF, Guha S, Wei Y, Wu TT, Chen CT, Kuo HP, Hsu JM, Sun HL, Chou CK, Buttar NS, Wang KK, Huang P, Ajani J, Hung MC. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res. 2008 Apr 15; 68(8):2632-40. PMID: 18413730; PMCID: PMC2377413.
-
Scott LC, Yao JC, Benson AB, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan; 63(2):363-70. PMID: 18398613.
-
Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 10; 26(8):1316-23. PMID: 18323556.
-
Baker J, Ajani JA. Proactive nurse management guidelines for managing intensive chemotherapy regimens in patients with advanced gastric cancer. Eur J Oncol Nurs. 2008 Jul; 12(3):227-32. PMID: 18329956.
-
Cen P, Hofstetter WL, Correa AM, Wu TT, Lee JH, Ross WA, Davilla M, Swisher SG, Fukami N, Rashid A, Maru D, Ajani JA. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer. 2008 Mar 1; 112(5):1020-7. PMID: 18205187.
-
Tetzlaff ED, Cen P, Ajani JA. Emerging drugs in the treatment of advanced gastric cancer. Expert Opin Emerg Drugs. 2008 Mar; 13(1):135-44. PMID: 18321153.
-
Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu C, Ajani JA, Phan A, Swisher SG, Mohan R, Cox JD, Komaki R. Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol. 2008 Mar; 3(3):277-82. PMID: 18317071.
-
Cen P, Tetzlaff ED, Ajani JA. Contribution of capecitabine for therapy of patients with gastroesophageal cancer: an update of recent phase III results. Ther Clin Risk Manag. 2008 Feb; 4(1):137-40. PMID: 18728703; PMCID: PMC2503649.
-
Cen P, Hofstetter WL, Lee JH, Ross WA, Wu TT, Swisher SG, Davila M, Rashid A, Correa AM, Ajani JA. Value of endoscopic ultrasound staging in conjunction with the evaluation of lymphovascular invasion in identifying low-risk esophageal carcinoma. Cancer. 2008 Feb 1; 112(3):503-10. PMID: 18072264.
-
Das P, Crane CH, Eng C, Ajani JA. Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res. 2008 Jan; 2(1):10-4. PMID: 19259318.
-
Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, Ajani JA, Crane CH, Krishnan S. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008; 47(3):421-7. PMID: 17899453.
-
Reed VK, Krishnan S, Mansfield PF, Bhosale PR, Kim M, Das P, Janjan NA, Delclos ME, Lowy AM, Feig BW, Pisters PW, Ajani JA, Crane CH. Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2008 Jul 1; 71(3):741-7. PMID: 18164837; PMCID: PMC4741525.
-
Ajani JA. The area between the curves gets no respect: is it because of the median madness? J Clin Oncol. 2007 Dec 1; 25(34):5531. PMID: 18048834.
-
Patel PR, Yao JC, Hess K, Schnirer I, Rashid A, Ajani JA. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer. 2007 Nov 15; 110(10):2186-90. PMID: 17896785.
-
Abraham SC, Krasinskas AM, Correa AM, Hofstetter WL, Ajani JA, Swisher SG, Wu TT. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol. 2007 Nov; 31(11):1719-25. PMID: 18059229.
-
Goldberg RM, Marshall JL, Ajani JA, Philip PA, O'Reilly EM, Venook AP. Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology. Gastrointest Cancer Res. 2007 Nov; 1(6 Suppl):S13-6. PMID: 19330058.
-
Kachnic LA, Ajani JA, Philip PA. Section II: Current Approaches to Treating Localized Gastrointestinal Cancers. Gastrointest Cancer Res. 2007 Nov; 1(6 Suppl):S4-7. PMID: 19330059.
-
Hochster HS, O'Reilly EM, Ajani JA, Venook AP. Section III: Treatment of Advanced Gastrointestinal Cancers. Gastrointest Cancer Res. 2007 Nov; 1(6 Suppl):S8-S12. PMID: 19330060.
-
Izzo JG, Ajani JA. Thinking in and out of the box when it comes to gastric cancer and cyclooxygenase-2. J Clin Oncol. 2007 Nov 1; 25(31):4865-7. PMID: 17971580.
-
Cen P, Ajani JA. Medical treatment for advanced gastroesophageal adenocarcinoma. Curr Opin Gastroenterol. 2007 Nov; 23(6):631-5. PMID: 17906439.
-
Ajani JA. Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge! Ann Surg Oncol. 2007 Dec; 14(12):3290-2. PMID: 17932722.
-
Ajani JA, Correa AM, Swisher SG, Wu TT. For localized gastroesophageal cancer, you give chemoradiation before surgery, but then what happens? J Clin Oncol. 2007 Sep 20; 25(27):4315-6. PMID: 17878485.
-
Patel PR, Mansfield PF, Crane CH, Wu TT, Lee JH, Lynch PM, Morris J, Pisters PW, Feig B, Sunder PK, Izzo JG, Ajani JA. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer. 2007 Sep 1; 110(5):989-95. PMID: 17636525.
-
Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007 Aug 20; 25(24):3719-25. PMID: 17704421.
-
Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van Cutsem E. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007 Aug 1; 25(22):3210-6. PMID: 17664468.
-
Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007 Aug 1; 25(22):3205-9. PMID: 17664467.
-
Hofstetter W, Correa AM, Bekele N, Ajani JA, Phan A, Komaki RR, Liao Z, Maru D, Wu TT, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Francis A, Blackmon S, Swisher SG. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg. 2007 Aug; 84(2):365-73; discussion 374-5. PMID: 17643602.
-
Das P, Crane CH, Ajani JA. Current treatment for localized anal carcinoma. Curr Opin Oncol. 2007 Jul; 19(4):396-400. PMID: 17545807.
-
Marshall JL, Haller DG, de Gramont A, Hochster HS, Lenz HJ, Ajani JA, Goldberg RM. Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrointest Cancer Res. 2007 Jul; 1(4):146-54. PMID: 19262703.
-
Izzo JG, Malhotra U, Wu TT, Luthra R, Correa AM, Swisher SG, Hofstetter W, Chao KS, Hung MC, Ajani JA. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev. 2007 Jun; 16(6):1200-5. PMID: 17548685.
-
Tetzlaff ED, Correa AM, Baker J, Ensor J, Ajani JA. The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. Cancer. 2007 May 15; 109(10):1989-95. PMID: 17397035.
-
Sakata Y, Ajani JA, Fujii M, Hyodo I, Kim YH. Global perspectives on chemotherapy for patients with gastric carcinoma: a roundtable discussion. Gastrointest Cancer Res. 2007 May; 1(3):107-14. PMID: 19262716.
-
Izzo JG, Luthra R, Wu TT, Correa AM, Luthra M, Anandasabapathy S, Chao KS, Hung MC, Aggarwal B, Hittelman WN, Ajani JA. Molecular mechanisms in Barrett's metaplasia and its progression. Semin Oncol. 2007 Apr; 34(2 Suppl 1):S2-6. PMID: 17449347.
-
Guerrero T, Johnson V, Hart J, Pan T, Khan M, Luo D, Liao Z, Ajani J, Stevens C, Komaki R. Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1030-5. PMID: 17398033.
-
Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CH. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 1; 68(3):794-800. PMID: 17379452.
-
Reid-Lombardo KM, Gay G, Patel-Parekh L, Ajani JA, Donohue JH. Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from theNational Cancer Data Base. J Gastrointest Surg. 2007 Apr; 11(4):410-9; discussion 419-20. PMID: 17436123; PMCID: PMC1852379.
-
Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene. 2007 Aug 16; 26(38):5674-9. PMID: 17353904.
-
Fujitani K, Ajani JA, Crane CH, Feig BW, Pisters PW, Janjan N, Walsh GL, Swisher SG, Vaporciyan AA, Rice D, Welch A, Baker J, Faust J, Mansfield PF. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol. 2007 Jul; 14(7):2010-7. PMID: 17342569.
-
Ajani JA. New proposal for postsurgery pathologic staging of esophageal or gastroesophageal junction adenocarcinoma: why bother? J Clin Oncol. 2007 Mar 1; 25(7):906-7; author reply 908-9. PMID: 17327615.
-
Ajani JA. Recent Developments in Cytotoxic Therapy for Advanced Gastric or Gastroesophageal Carcinoma: The Phase III Trials. Gastrointest Cancer Res. 2007 Mar; 1(2 Suppl):S16-21. PMID: 19343156.
-
Izzo JG, Wu TT, Wu X, Ensor J, Luthra R, Pan J, Correa A, Swisher SG, Chao CK, Hittelman WN, Ajani JA. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol. 2007 Feb 20; 25(6):698-707. PMID: 17308274.
-
Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Reseetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007 Feb 15; 109(4):658-67. PMID: 17211865.
-
Wang LW, Li Q, Hua ZL, Zhou F, Keping X, Daoyan W, Yao J, Ajani J. [Expression of transcription factor Sp1 in human gastric cancer tissue and its correlation with prognosis]. Zhonghua Zhong Liu Za Zhi. 2007 Feb; 29(2):107-11. PMID: 17645844.
-
Luthra MG, Ajani JA, Izzo J, Ensor J, Wu TT, Rashid A, Zhang L, Phan A, Fukami N, Luthra R. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res. 2007 Feb 1; 13(3):912-9. PMID: 17289885.
-
Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer. 2007 Jan 1; 109(1):33-40. PMID: 17133415.
-
Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL, Ajani JA. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 1; 13(1):234-40. PMID: 17200360.
-
Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007 Jan 1; 109(1):125-34. PMID: 17146785.
-
Ross WA, Alkassab F, Lynch PM, Ayers GD, Ajani J, Lee JH, Bismar M. Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. Gastrointest Endosc. 2007 Jan; 65(1):70-6. PMID: 17185082.
-
Wu TT, Chirieac LR, Abraham SC, Krasinskas AM, Wang H, Rashid A, Correa AM, Hofstetter WL, Ajani JA, Swisher SG. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007 Jan; 31(1):58-64. PMID: 17197919.
-
Izzo JG, Luthra R, Sims-Mourtada J, Chao KS, Lee JH, Wu TT, Correa AM, Luthra M, Aggarwal B, Hung MC, Ajani JA. Emerging molecular targets in esophageal cancers. Gastrointest Cancer Res. 2007; 1(4 Suppl 2):S3-6. PMID: 19360144.
-
Hu Z, Ajani JA, Wei Q. Molecular epidemiology of gastric cancer: current status and future prospects. Gastrointest Cancer Res. 2007 Jan; 1(1):12-9. PMID: 19262698.
-
Luthra R, Luthra MG, Izzo J, Wu TT, Lopez-Alvarez E, Malhotra U, Choi IS, Zhang L, Ajani JA. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin Oncol. 2006 Dec; 33(6 Suppl 11):S2-5. PMID: 17178277.
-
Rohatgi PR, Yao JC, Hess K, Schnirer I, Rashid A, Mansfield PF, Pisters PW, Ajani JA. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer. 2006 Dec 1; 107(11):2576-80. PMID: 17075877.
-
Ajani JA. Standard of care for gastric cancer based on meta-analysis? Treading on thin ice or it is very nice! J Clin Oncol. 2006 Dec 1; 24(34):5473-4; author reply 5474-6. PMID: 17135655.
-
Kanai M, Wei D, Li Q, Jia Z, Ajani J, Le X, Yao J, Xie K. Loss of Krüppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. Clin Cancer Res. 2006 Nov 1; 12(21):6395-402. PMID: 17085651.
-
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 1; 24(31):4991-7. PMID: 17075117.
-
Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB, Ajani JA. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther. 2006 Nov; 5(11):2844-50. PMID: 17121931.
-
Sims-Mourtada J, Izzo JG, Apisarnthanarax S, Wu TT, Malhotra U, Luthra R, Liao Z, Komaki R, van der Kogel A, Ajani J, Chao KS. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res. 2006 Nov 1; 12(21):6565-72. PMID: 17085672.
-
Shao L, Hittelman WN, Lin J, Yang H, Ajani JA, Wu X. Deficiency of cell cycle checkpoints and DNA repair system predispose individuals to esophageal cancer. Mutat Res. 2006 Dec 1; 602(1-2):143-50. PMID: 17011594.
-
Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW, Feig BW, Gunderson LL, Ajani JA. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer. 2006 Oct 1; 107(7):1475-82. PMID: 16944539.
-
Wang KL, Yang Q, Cleary KR, Swisher SG, Correa AM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation. Cancer. 2006 Oct 1; 107(7):1467-74. PMID: 16955509.
-
Wang SL, Liao Z, Liu H, Ajani J, Swisher S, Cox JD, Komaki R. Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World J Gastroenterol. 2006 Sep 14; 12(34):5501-8. PMID: 17006988.
-
Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Wu TT, Swisher SG. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006 Sep 1; 107(5):967-74. PMID: 16874819.
-
Ajani JA, Safran H, Bokemeyer C, Shah MA, Lenz HJ, Van Cutsem E, Burris HA, Lebwohl D, Mullaney B. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs. 2006 Sep; 24(5):441-6. PMID: 16586011.
-
Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006 Aug 20; 24(24):3953-8. PMID: 16921048.
-
Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, Ajani JA. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer. 2006 Aug 15; 107(4):676-85. PMID: 16847885.
-
Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D, Ajani J. Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer. 2006 Aug 21; 95(4):450-6. PMID: 16880795; PMCID: PMC2360664.
-
Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res. 2006 Aug 1; 12(15):4598-604. PMID: 16899607.
-
Ajani JA. Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. Expert Opin Pharmacother. 2006 Aug; 7(12):1627-31. PMID: 16872265.
-
Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, Han D, Bornmann WG, Ajani JA, Milas L, Gelovani JG, Chao KS. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res. 2006 Aug 1; 12(15):4590-7. PMID: 16899606.
-
Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer. 2006 Jul 15; 107(2):221-31. PMID: 16770784.
-
Ajani JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs. 2006 Jul; 24(4):353-7. PMID: 16683077.
-
Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006 Aug 10; 24(23):3789-98. PMID: 16785472.
-
Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA, Correa AM, Wu TT, Bruzzi JF, Marom EM, Sabloff BS, Ajani JA, Komaki R, Liao Z, Lee JH, Fukami N, Bresalier R, Swisher SG. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol. 2006 Jun; 1(5):478-86. PMID: 17409902.
-
Ajani JA. Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. Gan To Kagaku Ryoho. 2006 Jun; 33 Suppl 1:117-20. PMID: 16897985.
-
Ajani JA, Hecht JR, Ho L, Baker J, Oortgiesen M, Eduljee A, Michaeli D. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 2006 May 1; 106(9):1908-16. PMID: 16568451.
-
Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Esophageal Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4):328-47. PMID: 16569387.
-
Yasui W, Ajani JA, Nishiyama M, Ohtsu A, Tahara E. Current progress of cancer chemotherapy The Fifteenth International Symposium of the Hiroshima Cancer Seminar, October 2005. Cancer Sci. 2006 Apr; 97(4):328-31. PMID: 16630126.
-
Das P, Fukami N, Ajani JA. Combined modality therapy of localized gastric and esophageal cancers. J Natl Compr Canc Netw. 2006 Apr; 4(4):375-82. PMID: 16569390.
-
Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4):350-66. PMID: 16569388.
-
Wang S, Liao Z, Chen Y, Chang JY, Jeter M, Guerrero T, Ajani J, Phan A, Swisher S, Allen P, Cox JD, Komaki R. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol. 2006 Mar; 1(3):252-9. PMID: 17409865.
-
Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, Komaki RR, Rashid A, Hamilton SR, Wu TT. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006 Mar 1; 106(5):1017-25. PMID: 16456809.
-
Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB, Yanagihara R, Phan AT, Yao JC, Strumberg D. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006 Feb 1; 24(4):663-7. PMID: 16446338.
-
Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Bresalier RS, Roth JA, Ajani JA. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2006 Feb 1; 106(3):552-8. PMID: 16353210.
-
Clark OH, Ajani J, Benson AB, Byrd D, Doherty GM, Engstrom PF, Ettinger DS, Gibbs JF, Heslin MJ, Kandeel F, Kessinger A, Kulke MH, Kvols L, Nemcek AA, Olson JA, Ratliff TW, Saltz L, Schteingart DE, Shah MH, Shibata S. Neuroendocrine tumors. J Natl Compr Canc Netw. 2006 Feb; 4(2):102-38. PMID: 16451769.
-
Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, Aggarwal BB, Ajani JA. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006 Feb 10; 24(5):748-54. PMID: 16401681.
-
Tetzlaff ED, Faust J, Ajani JA. Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin. Gastric Cancer. 2006; 9(2):140-3. PMID: 16767371.
-
Rohatgi PR, Correa AM, Swisher SG, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Lee JH, Rice DC, Roth JA, Ajani JA. Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome. Dis Esophagus. 2006; 19(3):152-7. PMID: 16722991.
-
Song S, Lippman SM, Zou Y, Ye X, Ajani JA, Xu XC. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression. Oncogene. 2005 Dec 15; 24(56):8268-76. PMID: 16170369.
-
Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, Bailey J, Lee JH, Bresalier R, Rashid A, Swisher SG, Ajani JA. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006 Jan 10; 24(2):259-67. PMID: 16344314.
-
Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Lahoti S, Lee JH, Bresalier R, Roth JA, Swisher SG. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2006 Jan; 131(1):65-72. PMID: 16399296.
-
Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA, Ajani JA. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005 Dec 1; 104(11):2365-72. PMID: 16245310.
-
Shao L, Lin J, Huang M, Ajani JA, Wu X. Predictors of esophageal cancer risk: assessment of susceptibility to DNA damage using comet assay. Genes Chromosomes Cancer. 2005 Dec; 44(4):415-22. PMID: 16114035.
-
Ajani J, Allgood V. Molecular mechanisms in cancer: what should clinicians know? Semin Oncol. 2005 Dec; 32(6 Suppl 8):2-4. PMID: 16360003.
-
Izzo JG, Malhotra U, Wu TT, Ensor J, Babenko IM, Swisher SG, Correa A, Bresalier RS, Hittelman WN, Ajani JA. Impact of cyclin D1 A870G polymorphism in esophageal adenocarcinoma tumorigenesis. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S11-5. PMID: 16399423.
-
Wu X, Lu C, Chiang SS, Ajani JA. Pharmacogenetics in esophageal cancer. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S87-9. PMID: 16399440.
-
Das P, Ajani JA. Gastric and gastro-oesophageal cancer therapy. Expert Opin Pharmacother. 2005 Dec; 6(16):2805-12. PMID: 16318431.
-
Milas L, Raju U, Liao Z, Ajani J. Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S78-81. PMID: 16399438.
-
Ajani JA. Introduction. Semin Oncol. 2005 Dec; 32(6 Suppl 8):1. PMID: 16360002.
-
Liao Z, Liu H, Swisher SG, Wang L, Wu TT, Correa AM, Roth JA, Cox JD, Komaki R, Ajani JA, Wei Q. Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys. 2006 Mar 1; 64(3):700-8. PMID: 16242255.
-
Wang SL, Liao Z, Vaporciyan AA, Tucker SL, Liu H, Wei X, Swisher S, Ajani JA, Cox JD, Komaki R. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2006 Mar 1; 64(3):692-9. PMID: 16242257.
-
Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, Ajani JA. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer. 2005 Oct 15; 104(8):1620-6. PMID: 16118804.
-
Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005 Oct 15; 104(8):1590-602. PMID: 16134179.
-
Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh G, Vaporciyan A, Lynch PM, Rice DC, Roth JA, Ajani JA. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005 Oct 1; 104(7):1349-55. PMID: 16130133.
-
Ajani JA, Takimoto C, Becerra CR, Silva A, Baez L, Cohn A, Major P, Kamida M, Feit K, De Jager R. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Invest New Drugs. 2005 Oct; 23(5):479-84. PMID: 16133799.
-
Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005 Oct 1; 23(28):6957-65. PMID: 16145066.
-
Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005 Aug 20; 23(24):5660-7. PMID: 16110025.
-
Varadhachary G, Ajani JA. Preoperative and adjuvant therapies for upper gastrointestinal cancers. Expert Rev Anticancer Ther. 2005 Aug; 5(4):719-25. PMID: 16111471.
-
Esmaeli B, Golio D, Lubecki L, Ajani J. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol. 2005 Aug; 140(2):325-7. PMID: 16086962.
-
Liu L, Hofstetter WL, Rashid A, Swisher SG, Correa AM, Ajani JA, Hamilton SR, Wu TT. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol. 2005 Aug; 29(8):1079-85. PMID: 16006804.
-
Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005 May; 241(5):810-7; discussion 817-20. PMID: 15849517; PMCID: PMC1357136.
-
Agarwal B, Swisher SG, Ajani J, Kelly K, Komaki RR, Abu-Hamda E, Correa AM, Roth JA. Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux. Ann Thorac Surg. 2005 May; 79(5):1716-23. PMID: 15854962.
-
Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, Ajani JA. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005 May 1; 23(13):3094-103. PMID: 15860869.
-
Xu XC, Lee JJ, Wu TT, Hoque A, Ajani JA, Lippman SM. Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2005 Apr; 14(4):826-9. PMID: 15824151.
-
Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005 Apr 1; 103(7):1347-55. PMID: 15719440.
-
Ajani JA. Carcinoma of the esophagus: is biology screaming in my deaf ears? J Clin Oncol. 2005 Jul 1; 23(19):4256-8. PMID: 15781878.
-
Chirieac LR, Swisher SG, Correa AM, Ajani JA, Komaki RR, Rashid A, Hamilton SR, Wu TT. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res. 2005 Mar 15; 11(6):2229-36. PMID: 15788671.
-
Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 1; 61(3):656-64. PMID: 15708243.
-
Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005 Feb 20; 23(6):1237-44. PMID: 15718321.
-
Gong W, Wang L, Yao JC, Ajani JA, Wei D, Aldape KD, Xie K, Sawaya R, Huang S. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res. 2005 Feb 15; 11(4):1386-93. PMID: 15746037.
-
Varadhachary G, Ajani JA. Gastric cancer. Clin Adv Hematol Oncol. 2005 Feb; 3(2):118-24. PMID: 16166979.
-
Rice DC, Correa AM, Vaporciyan AA, Sodhi N, Smythe WR, Swisher SG, Walsh GL, Putnam JB, Komaki R, Ajani JA, Roth JA. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg. 2005 Feb; 79(2):391-7; discussionn 391-7. PMID: 15680801.
-
Chak A, Canto MI, Isenberg GA, Willis JE. EUS assessment of response to chemoradiation in esophageal cancer patients. Am J Gastroenterol. 2005 Feb; 100(2):496-7; author reply 497-9. PMID: 15667512.
-
Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, Zhang H, Cao L, Ajani JA, Xu XC. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis. 2005 Apr; 26(4):785-91. PMID: 15661803.
-
An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, Ajani JA, Rashid A, Hamilton SR, Wu TT. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):656-63. PMID: 15701853.
-
Wang L, Shi GG, Yao JC, Gong W, Wei D, Wu TT, Ajani JA, Huang S, Xie K. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer. 2005; 8(1):18-28. PMID: 15747170.
-
Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Walsh GL, Vaporciyan AA, Rice DC, Fukami N, Roth JA, Ajani JA. Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer. 2005; 36(2):69-76. PMID: 16648656.
-
Tetzlaff ED, Ajani JA. Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor. Int J Gastrointest Cancer. 2005; 36(1):55-8. PMID: 16227636.
-
Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005; 10 Suppl 3:49-58. PMID: 16368871.
-
Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Dec 1; 60(5):1484-93. PMID: 15590179.
-
Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004 Dec 1; 22(23):4762-71. PMID: 15570077.
-
Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004 Oct 15; 101(8):1776-85. PMID: 15386332.
-
Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004 Oct; 78(4):1152-60; discussion 1152-60. PMID: 15464463.
-
Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004 Oct 1; 60(2):427-36. PMID: 15380576.
-
Harting MT, Blakely ML, Herzog CE, Lally KP, Ajani JA, Andrassy RJ. Treatment issues in pediatric gastric adenocarcinoma. J Pediatr Surg. 2004 Aug; 39(8):e8-10. PMID: 15300556.
-
Whiting J, Sano T, Sasako M, Ajani JA. Report of the Seventeenth International Symposium of the Foundation for Promotion of Cancer Research: Recent Advances in Gastric Cancer. Jpn J Clin Oncol. 2004 Aug; 34(8):481-8. PMID: 15371468.
-
Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004 Aug 1; 101(3):518-26. PMID: 15274064.
-
Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004 Jul 15; 22(14):2918-26. PMID: 15254061.
-
Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS, Gunderson LL. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004 Jul 15; 22(14):2774-80. PMID: 15254045.
-
Agarwal B, Swisher S, Ajani J, Kelly K, Fanning C, Komaki RR, Putnam JB, Abu-Hamda E, Molke KL, Walsh GL, Correa AM, Ho L, Liao Z, Lynch PM, Rice DC, Smythe WR, Stevens CW, Vaporciyan AA, Yao J, Roth JA. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol. 2004 Jul; 99(7):1258-66. PMID: 15233663.
-
Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, Xie K. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4109-17. PMID: 15217947.
-
Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB, Lynch PM, Wu TT, Smythe R, Vaporciyan A, Faust J, Cohen DS, Nivers R, Roth JA. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004 Jun 1; 100(11):2347-54. PMID: 15160337.
-
Phan AT, Ajani JA. Gastric carcinoma. Curr Oncol Rep. 2004 May; 6(3):192-8. PMID: 15066230.
-
Ajani JA. Operate on my stomach cancer? Oh, no--not you, or not yet! J Clin Oncol. 2004 May 1; 22(9):1763-4; author reply 1764-5. PMID: 15118003.
-
Ueda Y, Yamagishi H, Yamashita T, Itoh N, Itoi H, Shirasaka T, Ajani JA. S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study. Jpn J Clin Oncol. 2004 May; 34(5):282-6. PMID: 15231865.
-
Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG, Goldberg RM. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004 May 15; 22(10):1785-96. PMID: 15067027.
-
Zheng L, Wang L, Ajani J, Xie K. Molecular basis of gastric cancer development and progression. Gastric Cancer. 2004; 7(2):61-77. PMID: 15224192.
-
Higuchi K, Koizumi W, Tanabe S, Saigenji K, Ajani JA. Chemotherapy is more active against proximal than distal gastric carcinoma. Oncology. 2004; 66(4):269-74. PMID: 15218293.
-
Xiong HQ, Ajani JA. Treatment of colorectal cancer metastasis: the role of chemotherapy. Cancer Metastasis Rev. 2004 Jan-Jun; 23(1-2):145-63. PMID: 15000155.
-
Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, Lynch PM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus. 2004; 17(1):38-43. PMID: 15209739.
-
Jiang Y, Wang L, Gong W, Wei D, Le X, Yao J, Ajani J, Abbruzzese JL, Huang S, Xie K. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis. 2004; 21(8):755-64. PMID: 16035620.
-
Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J, Xie K. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003 Dec 15; 9(17):6371-80. PMID: 14695137.
-
Lee HK, Vaporciyan AA, Cox JD, Tucker SL, Putnam JB, Ajani JA, Liao Z, Swisher SG, Roth JA, Smythe WR, Walsh GL, Mohan R, Liu HH, Mooring D, Komaki R. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys. 2003 Dec 1; 57(5):1317-22. PMID: 14630268.
-
Vauthey JN, Ajani JA. Liver transplantation and hepatocellular carcinoma biology: beginning of the end of the era of educated guesses. J Clin Oncol. 2003 Dec 1; 21(23):4265-7. PMID: 14581443.
-
Ajani JA. It's the poison that killed him, you say! J Clin Oncol. 2003 Oct 15; 21(20):3885. PMID: 14551310.
-
Higuchi K, Phan A, Ajani JA. Gastric cancer: advances in adjuvant and adjunct therapy. Curr Treat Options Oncol. 2003 Oct; 4(5):413-9. PMID: 12941201.
-
Swisher SG, Ajani JA, Komaki R, Nesbitt JC, Correa AM, Cox JD, Lahoti S, Martin F, Putnam JB, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2003 Sep 1; 57(1):120-7. PMID: 12909224.
-
Ajani JA, Faust J, Yao J, Komaki R, Stevens C, Swisher S, Putnam JB, Vaporciyan A, Smythe R, Walsh G, Rice D, Roth J. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):20-2. PMID: 14569843.
-
Ajani JA. Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):10-2. PMID: 14569840.
-
Xiong HQ, Gunderson LL, Yao J, Ajani JA. Chemoradiation for resectable gastric cancer. Lancet Oncol. 2003 Aug; 4(8):498-505. PMID: 12901965.
-
Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, Ajani JA. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003 Jul-Aug; 9(4):261-7. PMID: 12967136.
-
Lisenko Y, Kumar AJ, Yao J, Ajani J, Ho L. Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. Am J Clin Oncol. 2003 Apr; 26(2):165-70. PMID: 12714889.
-
Hung A, Crane C, Delclos M, Ballo M, Ajani J, Lin E, Feig B, Skibber J, Janjan N. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer. 2003 Mar 1; 97(5):1195-202. PMID: 12599225.
-
Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res. 2003 Jan; 9(1):134-42. PMID: 12538461.
-
Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol. 2003; 14 Suppl 2:ii41-4. PMID: 12810457.
-
Yao JC, Mansfield PF, Pisters PW, Feig BW, Janjan NA, Crane C, Ajani JA. Combined-modality therapy for gastric cancer. Semin Surg Oncol. 2003; 21(4):223-7. PMID: 14648779.
-
Schnirer II, Yao JC, Ajani JA. Carcinoid--a comprehensive review. Acta Oncol. 2003; 42(7):672-92. PMID: 14690153.
-
Ajani J, D'Amico TA, Hayman JA, Meropol NJ, Minsky B. Esophageal cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2003 Jan; 1(1):14-27. PMID: 19764147.
-
Ajani J, D'Amico TA, Hayman JA, Meropol NJ, Minsky B. Gastric cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2003 Jan; 1(1):28-39. PMID: 19764148.
-
Windham TC, Termuhlen PM, Ajani JA, Mansfield PF. Adenocarcinoma of the stomach in patients age 35 years and younger: no impact of early diagnosis on survival outcome. J Surg Oncol. 2002 Nov; 81(3):118-24; discussion 124-5. PMID: 12407722.
-
Report of the American Society for Therapeutic Radiology and Oncology Working Group on the scope of radiation oncology (SCOPE). Int J Radiat Oncol Biol Phys. 2002 Oct 1; 54(2):317-26. PMID: 12243803.
-
Gunderson LL, Sargent DJ, Tepper JE, O'Connell MJ, Allmer C, Smalley SR, Martenson JA, Haller DG, Mayer RJ, Rich TA, Ajani JA, Macdonald JS, Goldberg RM. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys. 2002 Oct 1; 54(2):386-96. PMID: 12243812.
-
Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5. PMID: 12192324; PMCID: PMC1422591.
-
Kasakura Y, Ajani JA, Mochizuki F, Morishita Y, Fujii M, Takayama T. Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer. J Surg Oncol. 2002 Aug; 80(4):181-5. PMID: 12210031.
-
Hasham-Jiwa N, Kasakura Y, Ajani JA. Brief review of advances in the treatment of gastric carcinoma in North America and Europe, 1995-2001. Int J Clin Oncol. 2002 Aug; 7(4):219-24. PMID: 12202975.
-
Ajani JA. Preoperative therapy for patients with resectable squamous cell carcinoma of the esophagus: are we still confused? Ann Surg Oncol. 2002 Aug; 9(7):605-6. PMID: 12167571.
-
Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology (Williston Park). 2002 Jun; 16(6 Suppl 6):89-96. PMID: 12108902.
-
Yao JC, Ajani JA. Adjuvant and preoperative chemotherapy for gastric cancer. Curr Oncol Rep. 2002 May; 4(3):222-8. PMID: 11937012.
-
Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2002 May; 16(5 Suppl 5):16-8. PMID: 12109800.
-
Kasakura Y, Ajani JA, Fujii M, Mochizuki F, Takayama T. Management of perforated gastric carcinoma: a report of 16 cases and review of world literature. Am Surg. 2002 May; 68(5):434-40. PMID: 12013286.
-
Kasakura Y, Phan A, Ajani J. Adjuvant therapy for resected gastric carcinoma. Surg Oncol Clin N Am. 2002 Apr; 11(2):431-44, xii-xiii. PMID: 12424861.
-
Ajani JA. [Is neoadjuvant therapy for locally advanced stomach carcinoma standard?]. Chirurg. 2002 Apr; 73(4):312-5. PMID: 12063914.
-
Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002 Feb 1; 94(3):641-6. PMID: 11857295.
-
Yao JC, Schnirer II, Reddy S, Chiang S, Najam A, Yu C, Giacco G, Hess K, Rashid A, Xie K, Lynch P, Ajani JA. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer. 2002; 5(4):208-12. PMID: 12491078.
-
Swisher SG, Wynn P, Putnam JB, Mosheim MB, Correa AM, Komaki RR, Ajani JA, Smythe WR, Vaporciyan AA, Roth JA, Walsh GL. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002 Jan; 123(1):175-83. PMID: 11782772.
-
Ajani JA. Docetaxel in combination for advanced gastric cancer. Gastric Cancer. 2002; 5 Suppl 1:31-4. PMID: 12772885.
-
Yao JC, Ajani JA. Therapy of localized gastric cancer: preoperative and postoperative approaches. Ann Oncol. 2002; 13 Suppl 4:7-12. PMID: 12401660.
-
Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, Gagel RF, Ajani JA, Wolff RA, Evans DB. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001 Dec; 130(6):1078-85. PMID: 11742342.
-
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 6; 345(10):725-30. PMID: 11547741.
-
Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer. 2001 Jul 15; 92(2):279-86. PMID: 11466680.
-
Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PW, Ajani JA, Mansfield PF. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol. 2001 Jul; 8(6):519-24. PMID: 11456051.
-
Tebbutt NC, Norman A, Hill M, Cunningham D. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol. 2001 May 15; 19(10):2765-7. PMID: 11352971.
-
Ajani JA, Baker J, Pisters PW, Ho L, Feig B, Mansfield PF. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 5):52-4. PMID: 11301842.
-
Schnirer II, Komaki R, Yao JC, Swisher S, Putnam J, Pisters PW, Roth JA, Ajani JA. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol. 2001 Feb; 24(1):91-5. PMID: 11232959.
-
Willett C, Ajani J, Kelsen D, Sigurdson E, Abrams R, Berkey B, Benetz M, Crane C, Gaspar L, Goodyear MD, Gunderson L, Haddock M, Hoffmann J, Janjan N, John M, Kachnic L, Krieg R, Landry J, Meropol N, Minsky B, Mitchell E, Mohiuddin M, Moulder J, Myerson R, Noyes D, Pajak TF, Raben D, Regine W, Rich T, Robertson JM, Russell A, Skibber J, Kim P. Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):19-27. PMID: 11641011.
-
Ajani J, Ettinger D, Kelsen DP, Hudis C, Kudelka A, Langer C, Pienta K, Safran H, Vokes EE, Yung WK. Radiation Therapy Oncology Group. Research Plan 2002-2006. Medical Oncology Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):88-91. PMID: 11641021.
-
Pro B, Lozano R, Ajani JA. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. Invest New Drugs. 2001; 19(4):341-3. PMID: 11561696.
-
Ajani JA. The evolving role of irinotecan: a broad-spectrum chemotherapeutic agent. Introduction. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):17-8. PMID: 11200142.
-
Ajani JA. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol. 2000 Dec 1; 18(23):4001-3. PMID: 11099333.
-
Swisher SG, Pisters PW, Komaki R, Lahoti S, Ajani JA. Gastroesophageal junction adenocarcinoma. Curr Treat Options Oncol. 2000 Dec; 1(5):387-98. PMID: 12057146.
-
Ajani JA, Fairweather J, Pisters PW, Charnsangavej C. Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):19-21. PMID: 11200143.
-
Komaki R, Janjan NA, Ajani JA, Lynch PM, Fairweather JS, Raijman I, Blumenshein GR, Ho L, Pisters PW, Feig BW, Walsh GL, Pazdur R. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):34-7. PMID: 11200147.
-
Ajani JA. [Strategies for preoperative therapy of locoregional cancers: an opportunity for expanding current concepts]. Chirurg. 2000 Dec; 71(12):1431-2. PMID: 11195060.
-
Yao JC, Ajani JA. Gastric cancer. Curr Opin Gastroenterol. 2000 Nov; 16(6):516-21. PMID: 17031130.
-
Swisher SG, Deford L, Merriman KW, Walsh GL, Smythe R, Vaporicyan A, Ajani JA, Brown T, Komaki R, Roth JA, Putnam JB. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg. 2000 Jun; 119(6):1126-32. PMID: 10838528.
-
Ajani JA, Yao JC. Preoperative therapy for local-regional gastric cancer: rationale and review of trials. Gan To Kagaku Ryoho. 2000 May; 27 Suppl 2:392-4. PMID: 10895184.
-
Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D. A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J. 2000 Mar-Apr; 6(2):78-81. PMID: 11069223.
-
Medgyesy CD, Wolff RA, Putnam JB, Ajani JA. Small cell carcinoma of the esophagus: the University of Texas M. D. Anderson Cancer Center experience and literature review. Cancer. 2000 Jan 15; 88(2):262-7. PMID: 10640955.
-
York JE, Stringer J, Ajani JA, Wildrick DM, Gokaslan ZL. Gastric cancer and metastasis to the brain. Ann Surg Oncol. 1999 Dec; 6(8):771-6. PMID: 10622506.
-
Yao JC, Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma: closing out the century. Oncology (Williston Park). 1999 Nov; 13(11):1485-94; discussion 1497-502 passim. PMID: 10581599.
-
Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials. Cancer. 1999 Nov 1; 86(9):1657-68. PMID: 10547537.
-
Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K, Curley S, Ota DM. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol. 1999 Aug; 17(8):2403-11. PMID: 10561303.
-
Partyka S, Dumas P, Ajani J. Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma. Cancer. 1999 Jun 1; 85(11):2336-9. PMID: 10357402.
-
Janjan NA, Abbruzzese J, Pazdur R, Khoo VS, Cleary K, Dubrow R, Ajani J, Rich TA, Goswitz MS, Evetts PA, Allen PK, Lynch PM, Skibber JM. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol. 1999 May; 51(2):153-60. PMID: 10435807.
-
Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999 Mar; 229(3):303-8. PMID: 10077040; PMCID: PMC1191693.
-
Ajani JA, Mansfield PF, Dumas P. Oral etoposide for patients with metastatic gastric adenocarcinoma. Cancer J Sci Am. 1999 Mar-Apr; 5(2):112-4. PMID: 10198733.
-
Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999 Feb; 17(2):600-6. PMID: 10080605.
-
Kim YH, Ajani JA, Carrasco CH, Dumas P, Richli W, Lawrence D, Chuang V, Wallace S. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest. 1999; 17(7):474-8. PMID: 10518191.
-
Ajani JA, Takiuchi H. Recent developments in oral chemotherapy options for gastric carcinoma. Drugs. 1999; 58 Suppl 3:85-90. PMID: 10711846.
-
Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998 Dec 31; 339(27):1979-84. PMID: 9869669.
-
NCCN practice guidelines for upper gastrointestinal carcinomas. National Comprehensive Cancer Network. Oncology (Williston Park). 1998 Nov; 12(11A):179-223. PMID: 10028512.
-
Ajani JA. Chemotherapy for gastric carcinoma: new and old options. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):44-7. PMID: 9830625.
-
Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol. 1998 Aug; 16(8):2877-85. PMID: 9704742.
-
Ajani JA. Current status of therapy for advanced gastric carcinoma. Oncology (Williston Park). 1998 Aug; 12(8 Suppl 6):99-102. PMID: 9726100.
-
Raijman I, Siddique I, Ajani J, Lynch P. Palliation of malignant dysphagia and fistulae with coated expandable metal stents: experience with 101 patients. Gastrointest Endosc. 1998 Aug; 48(2):172-9. PMID: 9717783.
-
Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am. 1998 Jul-Aug; 4(4):269-74. PMID: 9689986.
-
Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998 May; 16(5):1826-34. PMID: 9586897.
-
Rivera E, Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol. 1998 Feb; 21(1):36-8. PMID: 9499254.
-
Diamandidou E, Ajani JA, Yang DJ, Chuang VP, Brown CA, Carrasco HC, Lawrence DD, Wallace S. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol. 1998 Feb; 170(2):339-44. PMID: 9456942.
-
Thomas E, Dumas P, Ajani JA. Oral etoposide for patients with advanced adenocarcinoma of the pancreas. Invest New Drugs. 1998-1999; 16(4):333-5. PMID: 10426667.
-
Ajani JA. Current status of new drugs and multidisciplinary approaches in patients with carcinoma of the esophagus. Chest. 1998 Jan; 113(1 Suppl):112S-119S. PMID: 9438700.
-
Ajani JA, Pazdur R, Dumas P, Fairweather J. Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma. Invest New Drugs. 1998; 16(2):175-7. PMID: 9848582.
-
Pazdur R, Meyers C, Diaz-Canton E, Abbruzzese JL, Patt Y, Grove W, Ajani J. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. Am J Clin Oncol. 1997 Dec; 20(6):573-6. PMID: 9391543.
-
Ajani JA. Treatment of patients with upper gastrointestinal carcinomas. Semin Oncol. 1997 Dec; 24(6 Suppl 19):S19-72-S19-76. PMID: 9427271.
-
Ajani JA, Ilson DH, Kelsen DP. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. Semin Oncol. 1996 Oct; 23(5 Suppl 12):55-8. PMID: 8941411.
-
Lowy AM, Mansfield PF, Leach SD, Ajani J. Laparoscopic staging for gastric cancer. Surgery. 1996 Jun; 119(6):611-4. PMID: 8650600.
-
Wallace S, Ajani JA, Charnsangavej C, DuBrow R, Yang DJ, Chuang VP, Carrasco CH, Dodd GD. Carcinoid tumors: imaging procedures and interventional radiology. World J Surg. 1996 Feb; 20(2):147-56. PMID: 8661810.
-
Jeon HM, Lynch PM, Howard L, Ajani J, Levin B, Frazier ML. Mutation of the hMSH2 gene in two families with hereditary nonpolyposis colorectal cancer. Hum Mutat. 1996; 7(4):327-33. PMID: 8723682.
-
Ajani JA, Ilson DH, Kelsen DP. The activity of paclitaxel in gastrointestinal tumors. Semin Oncol. 1995 Oct; 22(5 Suppl 12):46-50; discussion 51-3. PMID: 7481861.
-
Pazdur R, Bready B, Ajani JA, Abbruzzese JL, Markowitz A, Sugarman S, Jones D, Levin B. Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. Am J Clin Oncol. 1995 Oct; 18(5):436-8. PMID: 7572763.
-
Rich TA, Skibber JM, Ajani JA, Buchholz DJ, Cleary KR, Dubrow RA, Levin B, Lynch PM, Meterissian SH, Roubein LD, et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys. 1995 Jul 15; 32(4):1025-9. PMID: 7607922.
-
Ajani JA, Ilson DH, Daugherty K, Kelsen DP. Paclitaxel in the treatment of carcinoma of the esophagus. Semin Oncol. 1995 Jun; 22(3 Suppl 6):35-40. PMID: 7541155.
-
Weinstein GD, Rich TA, Shumate CR, Skibber JM, Cleary KR, Ajani JA, Ota DM. Preoperative infusional chemoradiation and surgery with or without an electron beam intraoperative boost for advanced primary rectal cancer. Int J Radiat Oncol Biol Phys. 1995 Apr 30; 32(1):197-204. PMID: 7721616.
-
Ajani JA, Mansfield PF, Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World J Surg. 1995 Mar-Apr; 19(2):216-20. PMID: 7754626.
-
Kim YH, Ajani JA, Ota DM, Lynch P, Roth JA. Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer. 1995 Jan 15; 75(2):451-6. PMID: 7812915.
-
Leach SD, Lowy AM, Mansfield PF, Ajani JA. Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. J Infus Chemother. 1995; 5(3):104-11. PMID: 8528966.
-
Ajani JA. Therapy of carcinoma of the oesophagus: either attempt it not or succeed. Eur J Cancer. 1995; 31A(5):790-3. PMID: 7640055.
-
Ajani JA, Roth JA, Putnam JB, Walsh G, Lynch PM, Roubein LD, Ryan MB, Natrajan G, Gould P. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. Eur J Cancer. 1995; 31A(5):665-70. PMID: 7640036.
-
Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV, Markowitz AB, Abbruzzese JL, Bready B, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol. 1994 Nov; 12(11):2296-300. PMID: 7964943.
-
Kelsen D, Ajani J, Ilson D, Daugherty K, Pazdur R. A phase II trial of paclitaxel (Taxol) in advanced esophageal cancer: preliminary report. Semin Oncol. 1994 Oct; 21(5 Suppl 8):44-8. PMID: 7524158.
-
Ajani JA, Carrasco CH, Wallace S. Neuroendocrine tumors metastatic to the liver. Vascular occlusion therapy. Ann N Y Acad Sci. 1994 Sep 15; 733:479-87. PMID: 7978898.
-
Philip PA, Ajani JA. Has combined modality therapy improved the outlook in carcinoma of the esophagus? Oncology (Williston Park). 1994 Sep; 8(9):37-42; discussion 44-5, 50-2, 61. PMID: 7527642.
-
Ajani JA. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol. 1994 Aug; 21(4):474-82. PMID: 8042045.
-
Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994 Jul 20; 86(14):1086-91. PMID: 7912736.
-
Pazdur R, Lassere Y, Soh LT, Ajani JA, Bready B, Soo E, Sugarman S, Patt Y, Abbruzzese JL, Levin B. Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann Oncol. 1994 May; 5(5):468-70. PMID: 7915537.
-
Meterissian S, Skibber J, Rich T, Roubein L, Ajani J, Cleary K, Ota DM. Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma. Ann Surg Oncol. 1994 Mar; 1(2):111-6. PMID: 7834435.
-
Moore DF, Pazdur R, Abbruzzese JL, Ajani JA, Dubovsky DW, Wade JL, Belt RJ, Mangold C, Bready B, Winn RJ. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Ann Oncol. 1994 Mar; 5(3):286-7. PMID: 8186177.
-
Vassilopoulou-Sellin R, Ajani J. Islet cell tumors of the pancreas. Endocrinol Metab Clin North Am. 1994 Mar; 23(1):53-65. PMID: 7913029.
-
Ajani JA, Dodd LG, Daugherty K, Warkentin D, Ilson DH. Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst. 1994 Jan 5; 86(1):51-3. PMID: 7903699.
-
Ajani JA, Winn R, Baez L, Pollock T, Maher T, Hallinan-Fueger B, Newman J. Phase II study of merbarone (NSC 336628) in patients with advanced gastric carcinoma. Cancer Invest. 1994; 12(5):488-90. PMID: 7922705.
-
Rich TA, Ajani JA. High dose external beam radiation therapy with or without concomitant chemotherapy for esophageal carcinoma. Ann Oncol. 1994; 5 Suppl 3:9-15. PMID: 8204536.
-
Rich TA, Evans DB, Curley SA, Ajani JA. Adjuvant radiotherapy and chemotherapy for biliary and pancreatic cancer. Ann Oncol. 1994; 5 Suppl 3:75-80. PMID: 8204533.
-
Evans DB, Skibber JM, Lee JE, Cleary KR, Ajani JA, Gagel RF, Sellin RV, Fenoglio CJ, Merrell RC, Hickey RC. Nonfunctioning islet cell carcinoma of the pancreas. Surgery. 1993 Dec; 114(6):1175-81; discussion 1181-2. PMID: 7903005.
-
Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, Sugarbaker DJ, Dumas P, Gray C, Vena DA, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst. 1993 Nov 17; 85(22):1839-44. PMID: 8230264.
-
Jones DV, Patt YZ, Ajani JA, Abbruzzese J, Carrasco CH, Charnsangavej C, Levin B, Wallace S. A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. Cancer. 1993 Nov 1; 72(9):2560-3. PMID: 8402476.
-
Roubein LD, DuBrow R, David C, Lynch P, Fornage B, Ajani J, Roth J, Levin B. Endoscopic ultrasonography in the quantitative assessment of response to chemotherapy in patients with adenocarcinoma of the esophagus and esophagogastric junction. Endoscopy. 1993 Nov; 25(9):587-91. PMID: 8119209.
-
Shumate CR, Rich TA, Skibber JM, Ajani JA, Ota DM. Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. Cancer. 1993 Jun 1; 71(11):3690-6. PMID: 8490919.
-
Rich TA, Ajani JA, Morrison WH, Ota D, Levin B. Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. Radiother Oncol. 1993 Jun; 27(3):209-15. PMID: 8210457.
-
Pazdur R, Ajani JA, Patt YZ, Gomez J, Bready B, Levin B. Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. Cancer. 1993 Feb 15; 71(4):1214-8. PMID: 8435795.
-
Ajani JA, Abbruzzese JL, Markowitz AB, Patt YZ, Daugherty K. Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs. 1993 Feb; 11(1):67-9. PMID: 8349439.
-
Ajani JA, Chesnut JR. Response to increasing doses of octreotide in a patient with carcinoid syndrome. Eur J Cancer. 1993; 29A(16):2332-3. PMID: 7509166.
-
Jones DV, Ajani JA, Winn RJ, Daugherty KR, Levin B, Krakoff IH. A phase II study of merbarone in patients with adenocarcinoma of the pancreas. Cancer Invest. 1993; 11(6):667-9. PMID: 8221199.
-
Ajani JA. In rectal carcinoma, colostomy or no colostomy: is this the question? J Clin Oncol. 1993 Jan; 11(1):193-4. PMID: 8418233.
-
Ajani JA, Roth JA, Ryan MB, Putnam JB, Pazdur R, Levin B, Gutterman JU, McMurtrey M. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 1993 Jan; 11(1):22-8. PMID: 8418237.
-
Ajani JA, Dumas P. Evaluation of oral etoposide in patients with metastatic gastric carcinoma: a preliminary report. Semin Oncol. 1992 Dec; 19(6 Suppl 14):45-7. PMID: 1488653.
-
Hubbard KP, Pazdur R, Ajani JA, Braud E, Blaustein A, King M, Llenado-Lee M, Winn R, Levin B, Abbruzzese JL. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol. 1992 Dec; 15(6):524-7. PMID: 1449117.
-
Pazdur R, Ajani JJ, Abbruzzese JL, Belt RJ, Dakhil SR, Dubovsky D, Graham S, Pilat S, Winn R, Levin B. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer. 1992 Oct 15; 70(8):2073-6. PMID: 1394037.
-
Jones DV, Samaan NA, Sellin RV, Ajani JA. Metastatic glucagonoma: clinical response to a combination of 5-fluorouracil and alpha-interferon. Am J Med. 1992 Sep; 93(3):348-9. PMID: 1524091.
-
Jones DV, Ajani JA, Blackburn R, Daugherty K, Levin B, Patt YZ, Abbruzzese JL. Phase II study of didemnin B in advanced colorectal cancer. Invest New Drugs. 1992 Aug; 10(3):211-3. PMID: 1428730.
-
Grossie VB, Nishioka K, Ajani JA, Ota DM. Substituting ornithine for arginine in total parenteral nutrition eliminates enhanced tumor growth. J Surg Oncol. 1992 Jul; 50(3):161-7. PMID: 1619938.
-
Hubbard KP, Daugherty K, Ajani JA, Pazdur R, Levin B, Abbruzzese JL. Phase II trial of fazarabine in advanced colorectal carcinoma. Invest New Drugs. 1992 Apr; 10(1):39-42. PMID: 1376722.
-
Pazdur R, Ajani JA, Winn R, Bearden J, Belt RJ, Pilat S, Hallinan R, Levin B. A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma. Cancer. 1992 Feb 15; 69(4):878-82. PMID: 1735078.
-
Ajani JA, Ryan B, Rich TA, McMurtrey M, Roth JA, DeCaro L, Levin B, Mountain C. Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Eur J Cancer. 1992; 28A(4-5):880-4. PMID: 1524915.
-
Grossie VB, Ota DM, Ajani JA, Nishioka K. Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine. Invest New Drugs. 1991 Nov; 9(4):321-6. PMID: 1804805.
-
Linke K, Pazdur R, Abbruzzese JL, Ajani JA, Winn R, Bradof JE, Daugherty K, Levin B. Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs. 1991 Nov; 9(4):353-6. PMID: 1804812.
-
Ajani JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Belt R, Young J, Patt YZ, Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas. Invest New Drugs. 1991 Nov; 9(4):369-71. PMID: 1804816.
-
Ajani JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, Levin B, Jackson DE, Roh M, Hohn D. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer. 1991 Oct 1; 68(7):1501-6. PMID: 1893349.
-
Robey-Cafferty SS, Ajani JA, Ota DM, Roth JA, Bruner JM. Histologic observations and P-glycoprotein expression in gastric and esophageal adenocarcinomas treated with preoperative chemotherapy. Arch Pathol Lab Med. 1991 Aug; 115(8):807-12. PMID: 1713759.
-
Ajani JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Wiseman C, Lenado-Lee MA, Patt YZ, Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma. Invest New Drugs. 1991 Aug; 9(3):257-9. PMID: 1783525.
-
Nishioka K, Grossie VB, Chang TH, Ajani JA, Ota DM. Colorectal ornithine decarboxylase activity in human mucosa and tumors: elevation of enzymatic activity in distal mucosa. J Surg Oncol. 1991 Jun; 47(2):117-20. PMID: 2062082.
-
Ellerbroek NA, Fossella FV, Rich TA, Ajani JA, Komaki R, Roth JA, Holoye PY. Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1991 Feb; 20(2):351-5. PMID: 1846848.
-
Dhingra K, Talpaz M, Dhingra HM, Ajani JA, Rothberg JM, Gutterman JU. A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum. Invest New Drugs. 1991 Feb; 9(1):37-9. PMID: 1851142.
-
Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer. 1991 Jan 1; 67(1 Suppl):260-5. PMID: 1984825.
-
Pazdur R, Ajani JA, Patt YZ, Winn R, Jackson D, Shepard B, DuBrow R, Campos L, Quaraishi M, Faintuch J, et al. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol. 1990 Dec; 8(12):2027-31. PMID: 2230894.
-
Abbruzzese JL, Levin B, Ajani JA, Faintuch JS, Pazdur R, Saks S, Edwards C, Gutterman JU. A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity. J Biol Response Mod. 1990 Oct; 9(5):522-7. PMID: 2123922.
-
Ajani JA, Roth JA, Ryan B, McMurtrey M, Rich TA, Jackson DE, Abbruzzese JL, Levin B, DeCaro L, Mountain C. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 1990 Jul; 8(7):1231-8. PMID: 2358838.
-
Patt YZ, Lamki LM, Shanken J, Jessup JM, Charnsangavej C, Ajani JA, Levin B, Merchant B, Halverson C, Murray JL. Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. J Clin Oncol. 1990 Jul; 8(7):1246-54. PMID: 2193120.
-
Rich TA, Hughes L, Ajani JA, Brock W. Low dose, continuous infusion 5-fluorouracil plus radiotherapy for anal cancer. Int J Radiat Oncol Biol Phys. 1990 Mar; 18(3):710. PMID: 2318708.
-
Venkatesh S, Ordonez NG, Ajani J, Schultz PN, Hickey RC, Johnston DA, Samaan NA. Islet cell carcinoma of the pancreas. A study of 98 patients. Cancer. 1990 Jan 15; 65(2):354-7. PMID: 2153046.
-
Ajani JA, Abbruzzese JL, Faintuch JS, Patt YZ, Boman BM, Jackson DE, Levin B, Krakoff IH. A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. Cancer Invest. 1990; 8(6):619-21. PMID: 2149834.
-
Roth JA, Ajani JA, Rich TA. Multidisciplinary therapy for esophageal cancer. Adv Surg. 1990; 23:239-60. PMID: 2403459.
-
Nicaise C, Ajani J, Goudeau P, Rozencweig M, Levin B, Krakoff I. Phase II study of tallysomycin S10b in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 1990; 26(3):221-2. PMID: 1694112.
-
Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990; 8(2):147-59. PMID: 2400936.
-
Ajani JA, Ota DM, Grossie VB, Abbruzzese JL, Faintuch JS, Patt YZ, Jackson DE, Levin B, Nishioka K. Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma. Cancer Chemother Pharmacol. 1990; 26(3):223-6. PMID: 2113439.
-
Hughes LL, Rich TA, Delclos L, Ajani JA, Martin RG. Radiotherapy for anal cancer: experience from 1979-1987. Int J Radiat Oncol Biol Phys. 1989 Dec; 17(6):1153-60. PMID: 2599903.
-
Ajani JA, Levin B, Wallace S. Systemic and regional therapy of advanced islet cell tumors. Gastroenterol Clin North Am. 1989 Dec; 18(4):923-30. PMID: 2559037.
-
Grossie VB, Nishioka K, Chang TH, Patenia D, Benitez MM, Ajani JA, Ota DM. Differential effects of parenteral nutrition on tumor growth and erythrocyte polyamine levels in the rat. JPEN J Parenter Enteral Nutr. 1989 Nov-Dec; 13(6):590-5. PMID: 2515305.
-
Ajani JA, Ota DM, Grossie VB, Levin B, Nishioka K. Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels. Cancer Res. 1989 Oct 15; 49(20):5761-5. PMID: 2507135.
-
Ajani JA. Bolus fluorouracil for metastatic colorectal carcinoma? J Clin Oncol. 1989 Sep; 7(9):1366-7. PMID: 2769332.
-
Ajani JA, Kanojia MD, Bedikian AY. High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals. Am J Clin Oncol. 1989 Aug; 12(4):335-8. PMID: 2667325.
-
Grossie VB, Ota DM, Ajani JA, Chang TH, Patenia D, Nishioka K. Reduction of difluoromethylornithine-induced thrombocytopenia in rats with ornithine while maintaining antitumor activity. Cancer Res. 1989 Aug 1; 49(15):4159-62. PMID: 2501023.
-
Ajani JA, Carrasco CH, Jackson DE, Wallace S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med. 1989 Aug; 87(2):221-4. PMID: 2527006.
-
Abbruzzese JL, Levin B, Ajani JA, Faintuch JS, Saks S, Patt YZ, Edwards C, Ende K, Gutterman JU. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res. 1989 Jul 15; 49(14):4057-61. PMID: 2500234.
-
Hall JT, Wallace S, Carrasco CH, Charnsangavej C, Richli WR, Ajani J, Samaan N, Dodd GD. Gastrointestinal and pancreatic endocrine tumours. Baillieres Clin Endocrinol Metab. 1989 May; 3(1):121-52. PMID: 2679521.
-
Ajani JA, Rios AA, Ende K, Abbruzzese JL, Edwards C, Faintuch JS, Saks S, Gutterman JU, Levin B. Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. J Biol Response Mod. 1989 Apr; 8(2):140-6. PMID: 2499663.
-
Tueni EA, Newman RA, Baker FL, Ajani JA, Fan D, Spitzer G. In vitro activity of bleomycin, tallysomycin S10b, and liblomycin against fresh human tumor cells. Cancer Res. 1989 Mar 1; 49(5):1099-102. PMID: 2465080.
-
Ajani JA, Goudeau P, Levin B, Faintuch JS, Abbruzzese JL, Boman BM, Kanojia MD. Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. Cancer Chemother Pharmacol. 1989; 24(1):41-4. PMID: 2720890.
-
Nishioka K, Grossie VB, Ajani JA, Patenia D, Chang TH, Ota DM. Polyamine-directed preferential nutritional repletion of normal tissues in tumor-bearing hosts. Int J Cancer. 1988 Nov 15; 42(5):744-7. PMID: 3141298.
-
Ajani JA, Abbruzzese JL, Goudeau P, Faintuch JS, Yeomans AC, Boman BM, Nicaise C, Levin B. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol. 1988 Nov; 6(11):1703-7. PMID: 3141592.
-
Boman BM, Gagen MM, Bonnem E, Ajani JA, Schmidt S, Dimery IW, Golando J, Neidhart J. Phase I study of recombinant gamma-interferon (rIFN-gamma). J Biol Response Mod. 1988 Oct; 7(5):438-46. PMID: 3141591.
-
Grossie VB, Ota DM, Ajani JA, Chang TH, Patenia D, Nishioka K. Influence of total parenteral nutrition on tumor growth and polyamine biosynthesis of fibrosarcoma-bearing rats after induced cachexia. JPEN J Parenter Enteral Nutr. 1988 Sep-Oct; 12(5):441-4. PMID: 3141639.
-
Fan D, Baker FL, Khokhar AR, Ajani JA, Tomasovic B, Newman RA, Brock WA, Tueni E, Spitzer G. Antitumor activity against human tumor samples of cis-diamminedichloroplatinum(II) and analogues at equivalent in vitro myelotoxic concentrations. Cancer Res. 1988 Jun 1; 48(11):3135-9. PMID: 3365698.
-
Ajani JA, Baker FL, Spitzer G. In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. Invest New Drugs. 1988 Jun; 6(2):79-85. PMID: 3170133.
-
Ajani JA, Abbruzzese JL, Faintuch JS, Blackburn R, Levin B, Boman BM. Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. Invest New Drugs. 1988 Apr; 6(1):47-50. PMID: 2457566.
-
Baker FL, Ajani J, Spitzer G, Tomasovic BJ, Williams M, Finders M, Brock WA. High colony-forming efficiency of primary human tumor cells cultured in the adhesive-tumor-cell culture system: improvements with medium and serum alterations. Int J Cell Cloning. 1988 Mar; 6(2):95-105. PMID: 3373036.
-
Ajani JA, Carrasco CH, Charnsangavej C, Samaan NA, Levin B, Wallace S. Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med. 1988 Mar; 108(3):340-4. PMID: 2449109.
-
Baker FL, Spitzer G, Ajani JA, Brock WA. Drug and radiation sensitivity testing of primary human tumor cells using the adhesive-tumor-cell culture system (ATCCS). Prog Clin Biol Res. 1988; 276:105-17. PMID: 3174675.
-
Ajani JA, Baker FL, Spitzer G, Kelly A, Brock W, Tomasovic B, Singletary SE, McMurtrey M, Plager C. Comparison between clinical response and in vitro drug sensitivity of primary human tumors in the adhesive tumor cell culture system. J Clin Oncol. 1987 Dec; 5(12):1912-21. PMID: 3681375.
-
Fan D, Ajani JA, Baker FL, Tomasovic B, Brock WA, Spitzer G. Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system: an in vitro method of screening new drugs. Eur J Cancer Clin Oncol. 1987 Oct; 23(10):1469-76. PMID: 2890527.
-
Odaimi M, Ajani J. High-dose chemotherapy. Concepts and strategies. Am J Clin Oncol. 1987 Apr; 10(2):123-32. PMID: 3551575.
-
Ajani JA, Hortobagyi GN, Frye D, Levin B, Boman BM, Faintuch JS. A randomized study of two schedules of copovithane in patients with advanced colorectal carcinoma. Am J Clin Oncol. 1987 Apr; 10(2):139-40. PMID: 3551577.
-
Grossie VB, Ota DM, Ajani JA, Nishioka K. Effect of intravenous alpha-difluoromethylornithine on the polyamine levels of normal tissue and a transplantable fibrosarcoma. Cancer Res. 1987 Apr 1; 47(7):1836-40. PMID: 3102050.
-
Singletary SE, Baker FL, Spitzer G, Tucker SL, Tomasovic B, Brock WA, Ajani JA, Kelly AM. Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res. 1987 Jan 15; 47(2):403-6. PMID: 3491676.
-
Ajani JA, Spitzer G, Tomasovic B, Drewinko B, Hug VM, Dicke K. In vitro cytotoxicity patterns of standard and investigational agents on human bone marrow granulocyte-macrophage progenitor cells. Br J Cancer. 1986 Oct; 54(4):607-13. PMID: 3778805.
-
Odaimi M, Ajani JA. Brain metastases and elevated alpha-fetoprotein level in a patient with esophageal carcinoma. South Med J. 1986 Oct; 79(10):1304-6. PMID: 2429372.
-
Patt YZ, Boddie AW, Charnsangavej C, Ajani JA, Wallace S, Soski M, Claghorn L, Mavligit GM. Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer. J Clin Oncol. 1986 Sep; 4(9):1356-64. PMID: 2943876.
-
Ota DM, Grossie VB, Ajani JA, Stephens LC, Nishioka K. Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion. Int J Cancer. 1986 Aug 15; 38(2):245-9. PMID: 3089944.
-
Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol. 1986 Jul; 147(1):149-54. PMID: 2424291.
-
Schosser RH. Toxic reaction to prolonged high-dose fluorouracil. JAMA. 1986 Jun 13; 255(22):3116. PMID: 2939267.
-
Adolphson CC, Ajani JA, Stroehlein JR, Barlogie B, Bodey GP, Korinek J, Bedikian AY. Phase II trial of acivicin in patients with advanced colorectal carcinoma. Am J Clin Oncol. 1986 Jun; 9(3):189-91. PMID: 3728371.
-
Ajani JA, Dimery I, Chawla SP, Pinnamaneni K, Benjamin RS, Legha SS, Krakoff IH. Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas. Cancer Treat Rep. 1986 Mar; 70(3):375-9. PMID: 3955548.
-
Baker FL, Spitzer G, Ajani JA, Brock WA, Lukeman J, Pathak S, Tomasovic B, Thielvoldt D, Williams M, Vines C, et al. Drug and radiation sensitivity measurements of successful primary monolayer culturing of human tumor cells using cell-adhesive matrix and supplemented medium. Cancer Res. 1986 Mar; 46(3):1263-74. PMID: 3484678.
-
Ajani JA, Tomasovic B, Spitzer G, Kavanagh JJ, Thielvoldt D, Baker FL, Gershenson D. Activity of 2-fluoro-Ara AMP against gynecologic tumors in the soft agar assay. Invest New Drugs. 1986; 4(2):141-8. PMID: 2426218.
-
Ajani JA, Faintuch JS, McClure RK, Levin B, Boman BM, Krakoff IH. Phase II study of spirogermanium in patients with advanced colorectal carcinoma. Invest New Drugs. 1986; 4(4):383-5. PMID: 3583645.
-
Umbach GE, Spitzer G, Ajani JA, Hug V, Thames H, Rudolph FB, Drewinko B. Role of culture conditions and exposure duration in determining sensitivity of human bone marrow progenitor cells to methotrexate. J Cancer Res Clin Oncol. 1986; 111(3):273-6. PMID: 3733857.
-
Hortobagyi GN, Papadoupoulos NE, Frye D, Ajani J, Reuben JM. Phase I clinical study of nafazatrom. Invest New Drugs. 1986; 4(3):251-5. PMID: 3818230.
-
Feldman LD, Ajani JA. Fluorouracil-associated dermatitis of the hands and feet. JAMA. 1985 Dec 27; 254(24):3479. PMID: 2933539.
-
Harris WB, Grossie VB, Ota DM, Nishioka K, Ajani JA, Chang T, Patenia D. Effect of difluoromethylornithine on host and tumor polyamine metabolism during total parenteral nutrition. J Surg Res. 1985 Jun; 38(6):592-8. PMID: 3925242.
-
Singletary SE, Umbach GE, Spitzer G, Drewinko B, Tomasovic B, Ajani J, Hug V, Blumenschein G. The human tumor stem cell assay revisited. Int J Cell Cloning. 1985 Mar; 3(2):116-28. PMID: 3998518.
-
Ajani JA, Kanojia MD, Bedikian AY, Korinek JK, Stein SH, Espinoza EG, Bodey GP. Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma. Am J Clin Oncol. 1985 Feb; 8(1):69-71. PMID: 3993626.
-
Kantarjian H, Ajani JA, Karlin DA. Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology. 1985; 42(2):69-71. PMID: 3921891.
-
Ajani JA, Blaauw AA, Spitzer G, Baker FL, Tomasovic B, Umbach G, Thielvoldt D, Zander AR, Dicke KA. Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro. Exp Hematol. 1985; 13 Suppl 16:95-100. PMID: 2580731.
-
Umbach GE, Hug V, Spitzer G, Tomasovic B, Thames H, Ajani JA, Drewinko B. Survival of human bone marrow cells after in vitro treatment with 12 anticancer drugs and implications for tumor drug sensitivity assays. J Cancer Res Clin Oncol. 1985; 109(2):130-4. PMID: 3980561.
-
Ajani JA, Kanojia MD, Bodey GP. Phase II evaluation of 4'-epi-doxorubicin in patients with metastatic colorectal carcinoma. Cancer Treat Rep. 1984 Dec; 68(12):1507-8. PMID: 6595058.
-
Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep. 1984 Sep; 68(9):1085-91. PMID: 6478448.
-
Feun LG, Savaraj N, Bodey GP, Lu K, Yap BS, Ajani JA, Burgess MA, Benjamin RS, McKelvey E, Krakoff I. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res. 1984 Aug; 44(8):3608-12. PMID: 6744283.
-
Legha SS, Ajani JA, Blumenschein GR, Hortobagyi GN, Buzdar AU. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer. 1984 May 1; 53(9):1836-40. PMID: 6231092.
-
Spitzer G, Baker F, Umbach G, Hug V, Tomasovic B, Ajani J, Haynes M, Sahu SK. Growth factor enhancement of the in vitro stem cell assay. Recent Results Cancer Res. 1984; 94:253-66. PMID: 6593776.
-
Kanojia M, Kantarjian H, Ajani J, Barlogie B. High-dose cytosine arabinoside (Ara-C) in colorectal cancer. Br J Cancer. 1983 Dec; 48(6):869-71. PMID: 6652028; PMCID: PMC2011573.
-
Legha SS, Ajani JA, Bodey GP. Phase I study of spirogermanium given daily. J Clin Oncol. 1983 May; 1(5):331-6. PMID: 6668504.
-
Ajani JA, Burgess MA. Multiple squamous cell carcinoma treated with intra-arterial cisplatin in a patient with rheumatoid arthritis. Cancer Treat Rep. 1982 Nov; 66(11):1987-9. PMID: 6890408.
-
Ajani JA, Cabanillas FF, Bodey GP. Phase I trial of pentamethylmelamine. Cancer Treat Rep. 1982 May; 66(5):1227-8. PMID: 6805950.
-
In reply [19]. Journal of Clinical Oncology. 23:3870-3871.
-
Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy. Annals of Surgical Oncology. 23:626-632.
-
Role of chemotherapy for advanced/recurrent gastric cancer. JAMA - Journal of the American Medical Association. 49:1565-1577.
-
Cancer single pathways inhibitors. Gastric and Breast Cancer. 11:111-117.
-
H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-β-Catenin Signaling in Colorectal Cancer. EBioMedicine. 13:113-124.
-
American Society of Clinical Oncology, 45th Annual Meeting - Comparison of cisplatin/S-1 tablets with cisplatin/5-FU infusions for advanced gastric cancer. P and T. 34:379-380.
-
Erratum. Cancer. 115:2024.
-
Seminars in Oncology. Seminars in Oncology. 32:1.
-
How much luminal dilation (if any) is necessary prior to placement of an esophageal Wallstent?. Gastrointestinal Endoscopy. 45.
-
Management of a rectovesical malignant fistula with the coated wallstent. Gastrointestinal Endoscopy. 45.
-
Erratum. Cancer. 120:3264.
-
A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. American Journal of Clinical Oncology: Cancer Clinical Trials.
-
A nomogram to predict distant metastases after multimodality therapy for patients with localized esophageal cancer. JNCCN Journal of the National Comprehensive Cancer Network. 14:173-179.
-
Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ. Hepatology.
-
Palliation of malignant colorectal strictures with expandable metallic stents. Gastrointestinal Endoscopy. 47.
-
Editor's commentary. Current Colorectal Cancer Reports. 1:1.
-
Gastrointestinal malignancies in the elderly. Cancer Bulletin. 47:218-223.
-
18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. European Journal of Cancer.
-
Adjuvant therapy for resected gastric carcinoma. Surgical Oncology Clinics of North America. 11:431-444.
-
Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clinic Proceedings. 91:1307-1318.
-
The biology of K-Ras and B-Raf mutations in colorectal cancer. Current Colorectal Cancer Reports. 6:206-211.
-
Seminars in oncology. Seminars in Oncology. 29:1-2.
-
Survival rates in T1 and T2 gastric cancer. Journal of Surgical Oncology. 114:602-606.
-
Reply to D. Vordermark. Journal of Clinical Oncology. 27:3065.
-
Adjuvant chemotherapy of colorectal cancer. Cancer Bulletin. 40:235-238.
-
In Reply. JAMA - Journal of the American Medical Association. 255:3116.
-
Barrett's esophagus. Gastrointestinal Cancer Research. 5:49-53.
-
In reply [2]. Journal of Clinical Oncology. 25:5529-5530.
-
Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. American Journal of Dermatopathology. 21:36-38.
-
Surgical Resection first for localized gastric adenocarcinoma. Journal of Clinical Oncology. 33:3085-3091.
-
Corrigendum to "Docetaxel-related side effects and their management" [European Journal of Oncology Nursing 12 (2008) 253-268] (DOI. European Journal of Oncology Nursing. 12:479.
-
Conservative management of anal and low rectal cancers with combined modality therapy. Cancer Bulletin. 41:71-74.
-
Status of newer chemotherapeutic strategies for the treatment of metastatic gastric cancer. American Journal of Cancer. 4:65-70.
-
Erratum. Current Opinion in Gastroenterology. 24:101.
-
Neoadjuvant therapy for gastric cancer. Asian Journal of Surgery. 24:235-241.
-
Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Annals of Surgical Oncology. 1-11.
-
Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Annals of Surgical Oncology. 1-6.
-
Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy. Oncology (Switzerland). 91:55-60.
-
The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology (Switzerland).
-
The role of docetaxel in gastric cancer. European Journal of Cancer, Supplement. 4:4-9.
-
The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clinical Cancer Research. 21:2580-2590.
-
HER2 testing and clinical decision making in gastroesophageal adenocarcinoma. Archives of Pathology and Laboratory Medicine. 140:1345-1363.
-
Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology. JNCCN Journal of the National Comprehensive Cancer Network. 14:1286-1312.
-
Outcome of preoperative chemoradiation in localized gastric adenocarcinoma. American Journal of Hematology/ Oncology. 6:142-145.
-
Ramucirumab for the treatment of gastroesophageal cancers. Expert Opinion on Orphan Drugs. 3:737-746.
-
Development and validation of a six-gene recurrence risk score assay for gastric cancer. Clinical Cancer Research. 22:6228-6235.
-
Introduction. Seminars in Oncology. 34.
-
Adjuvant and neoadjuvant therapy for gastric cancer. Gastrointestinal Cancer Research. 5:203-204.
-
Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology (Switzerland).
-
Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. Clinical Gastroenterology and Hepatology. 13:1730-1737.
-
The effect of spontaneous and induced cachexia on hepatic and tumor polyamine metabolism. 143-150.
-
Proteomics approach to identify biomarkers for upper gastrointestinal cancer. Expert Review of Proteomics. 13:1041-1053.
-
In reply. Journal of Clinical Oncology. 27:468-469.
-
GCR graduates from nursery school on a fast track to editorial excellence. Gastrointestinal Cancer Research. 4:39.
-
Introduction. Seminars in Oncology. 33:1.
-
Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Annals of Surgical Oncology.
-
Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma. The Lancet Oncology. 17:1628-1629.
-
Early clinical esophageal adenocarcinoma (cT1). European Journal of Radiology. 88:56-60.
-
Paraneoplastic neurological syndromes associated with gastric cancer. Clinical Journal of Gastroenterology. 5:355-360.
-
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut. 64:1721-1731.
-
Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Review of Gastroenterology and Hepatology. 10:383-392.
-
Response. Gastrointestinal Endoscopy. 76:1073-1075.
-
Gastroesophageal cancers. 3-4.
-
Current therapeutic approaches to localized carcinoma of the esophagus and gastroesophageal junction. Clinical Practice. 9:463-471.
-
Adhesive tumor cell culture system.
-
Anal canal cancer. Expert Opinion on Orphan Drugs. 2:137-146.
-
Management of advanced gastric cancer.
-
The overall complication rate after esophageal Wallstent is related to the esophageal location of the lesion. Gastrointestinal Endoscopy. 45.
-
Esophageal Adenocarcinoma. 67-86.
-
Tumor factors that may affect the outcome after palliation with the esophageal Wallstent?. Gastrointestinal Endoscopy. 45.
-
In reply [5]. Journal of Clinical Oncology. 25:2491-2493.
-
Therapeutic options for patients with advanced islet cell and carcinoid tumors. Regional Cancer Treatment. 3:235-242.
-
Quality Indicators for the Management of Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma. Gastroenterology. 149:1599-1606.
-
ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. Oncotarget. 6:25883-25896.
-
Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Annals of Surgical Oncology. 1-8.
-
Author reply [4]. Cancer. 109:1449.
-
Operative and adjuvant treatment strategies for gastric carcinoma. Cancer Bulletin. 44:286-291.
-
Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets. Annals of Surgical Oncology. 1-6.
-
Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Annals of Surgical Oncology. 1-6.
-
1988 American Society of Clinical Oncology Meeting (ASCO 1988) - New Orleans, May 23-25, 1988. Journal of Cancer Research and Clinical Oncology. 114:533-535.
-
Palliation of malignant gastric outlet and duodenal obstruction using expandable metallic stents. Gastrointestinal Endoscopy. 47.
-
Group organizational structure. International Journal of Radiation Oncology Biology Physics. 51:6-10.
-
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. British Journal of Cancer.
-
The best timing for administering systemic chemotherapy in patients with locally advanced rectal cancer. Annals of Translational Medicine. 4.
-
The emerging epidemic of gastroesophageal cancers. Oncology. 21.
-
A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. Journal of Gastrointestinal Oncology. 6:45-52.
-
The role of PI3K/PTEN/AKT/mTOR genetic variation in clinical outcomes following chemoradiotherapy for esophageal cancer. American Journal of Hematology/ Oncology. 8.
-
Palliation of malignant dysphagia with chemoradiation therapy (ChXRT) does not increase the rate of serious complications with coated Wallstent. Gastrointestinal Endoscopy. 45.
-
Activity of investigational agents.
-
Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer. Journal of Gastrointestinal Oncology. 7:499-505.
-
Global chemotherapy development for gastric cancer. Gastric Cancer. 1-10.
-
Palliation of malignant dysphagia and fistulae with the Wwallstent. Gastrointestinal Endoscopy. 45.
-
In reply. Gastrointestinal Cancer Research. 3:218.
-
Chemotherapy and radiotherapy for anal canal carcinoma - Reply. JAMA - Journal of the American Medical Association. 300:1411.
-
Genome-based diagnostics and therapeutics in personalized cancer therapy. Gastric and Breast Cancer. 11:53-57.
-
Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation. Oncology (Switzerland).
-
Seminars in Oncology. Seminars in Oncology. 32.
-
In reply. Journal of Clinical Oncology. 26:2236-2237.
-
Is targeted therapy possible for patients with gastric adenocarcinoma?. Expert Opinion on Pharmacotherapy. 1-4.
-
Oxaliplatin beim kolorektal-karzinom. Onkologie. 25:1-11.
-
Phase I study of spirogermanium (SPG) given for five consecutive days per week.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
| Year | Publications |
|---|
| 1982 | 2 | | 1983 | 2 | | 1984 | 5 | | 1985 | 7 | | 1986 | 13 | | 1987 | 6 | | 1988 | 10 | | 1989 | 13 | | 1990 | 11 | | 1991 | 10 | | 1992 | 9 | | 1993 | 12 | | 1994 | 14 | | 1995 | 10 | | 1996 | 4 | | 1997 | 2 | | 1998 | 13 | | 1999 | 11 | | 2000 | 11 | | 2001 | 10 | | 2002 | 18 | | 2003 | 18 | | 2004 | 22 | | 2005 | 41 | | 2006 | 37 | | 2007 | 40 | | 2008 | 34 | | 2009 | 33 | | 2010 | 26 | | 2011 | 27 | | 2012 | 28 | | 2013 | 32 | | 2014 | 19 | | 2015 | 25 | | 2016 | 3 | | 2017 | 2 | | 2018 | 1 |
To return to the timeline, click here.
|
AJANI's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|